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Summary	  
	  
The main focus of this study was to use mass spectrometry-based proteomics to study 
protein abundance in cerebrospinal fluid (CSF) to reveal proteins that could serve as 
biomarker candidates in multiple sclerosis (MScl). 
 
By combining a CSF pooling strategy and label-free relative quantification we 
discovered 65 proteins of differential abundance between MScl patients and controls. 
A selection of 17 biomarker candidates was further subjected to two independent 
verification steps: using stable isotope dimethyl labeling coupled to Accurate 
Inclusion Mass Screening (dimethyl-AIMS) and Stable Isotope Dilution Selected 
Reaction Monitoring (SID-SRM) for targeted quantification. The SID-SRM study 
included a larger patient cohort of 125 cases and controls. To our knowledge, this is 
the first report of a larger SRM verification study for biomarker candidates in MScl. 
The most interesting results from the biomarker discovery and verification study were 
the significantly decreased abundance of Apolipoprotein D, Cystatin C, Kallikrein-6 
and Alpha-1-acid glycoprotein 1 in MScl patients compared to controls.  
Furthermore, we performed a comprehensive characterization of the normal 
CSF proteome. We identified 18, 807 peptide mapping to 1987 proteins by applying 
immuno-affinity depletion and SDS-PAGE for enhanced proteome coverage. We 
obtain a comprehensive set of reference proteins that could further be used for 
investigations in MScl. The experiment gave us the opportunity to examine the size 
distribution on the SDS-PAGE gel of a selection of biomarker candidate proteins in 
normal CSF, with the aim to reveal potential protein variants (isoforms, truncation 
products and proteolytic processed products). We hypothesized that the identification 
of non-tryptic peptides could indicate truncation products of proteins in CSF. 13 and 
nine non-tryptic peptides were identified for the biomarker candidates Cystatin C and 
Secretogranin-1, respectively. This information had immediate utility for 
investigation in MScl. Based on the observed spread in size distribution of biomarker 
candidate proteins in normal CSF, we aimed to obtain quantitative information of 
proteins present in both high and low mass fractions on the gel and further target these 
proteins to obtain an abundance ratio between RRMS (patients) and OIND (controls), 
and investigate if these ratios differed for the same protein. The most striking 
observation was the opposite regulation level in CSF of Secretogranin-1. 	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1 Introduction	  
 
1.1	  Multiple	  sclerosis	  
 
Multiple Sclerosis (MScl) is an inflammatory and neurodegenerative disease 
associated with localized destruction of myelin sheaths and axons in the central 
nervous system (CNS) (Ferguson, Matyszak et al. 1997; Jacobs, Beck et al. 2000). 
The name of the disease refers to the multiple chronic sclerotic lesions scattered 
throughout the brain and spinal cord of MScl patients (Compston and Coles 2002), 
and could also refer to the multiple relapses and remissions characterized by the 
disease. A relapse is a symptom believed to result from lesion formation in the CNS 
whereof axonal demyelination suppresses the conduction of nervous signals 
(Noseworthy, Lucchinetti et al. 2000). Dependent on the location of the lesion, 
different symptoms occurs in the periphery of the CNS. Remission or recovery is a 
return to the baseline state that existed prior the last relapse and are believed to result 
from remyelination of the damaged myelin.  
 
1.1.1	  The	  multiple	  sclerosis	  patient	  
 
MScl is the most common disabling neurological disease affecting young adults, with 
disease onset normally occurring at the age between 20-40 (Rejdak, Jackson et al. 
2010).  A clear gender difference is observed whereof MScl affects twice as many 
women as it does men. Worldwide, the disease affects approximately 2.5 million 
people, predominantly affecting northern Europeans (Compston and Coles 2002). In 
Norway the prevalence of MScl is ~151-180/100 000 (Grytten, Glad et al. 2006). The 
overall cause of MScl is still unknown, the most accepted theory is that MScl is 
triggered by environmental factors, such as virus infections (Dalgleish 1997) or 
vitamin D deficiency, in genetic susceptible individuals (Sadovnick, Ebers et al. 
1996).  
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1.1.2	  Inflammation	  and	  neurodegeneration	  in	  multiple	  sclerosis	  
 
Myelin sheaths make up the principle target of immune attack in MScl (Figure I). 
Under normal conditions myelin sheaths serves as insulating segments needed for 
saltatory conduction, increasing the propagation efficiency of nervous impulses. As a 
consequence of the demyelinating events of MScl the signal transduction along the 
axons in the CNS is impaired, thus hampering the transmission of signals from CNS 
to the periphery. The area in the periphery may become affected with a variety of 
symptoms. The signs and symptoms of relapses are diverse, and include among others 
optic neuritis, weakness in limbs, cognitive impairment, tremor and fatigue 
(Compston and Coles 2008). 
 
 
 
Figure I: Demyelination. A normal axon contains intact myelin sheaths that increase the efficiency of 
action potential propagation along the nerve cell. Due to the demyelinating process of MScl axons in 
lesion areas destroyed and the conduction of axonal impulses are inhibited. Adapted from (Trapp and 
Nave 2008).  
 
The	  hallmarks	  of	  multiple	  sclerosis	  
The pathology of MScl is distinguished from that of other inflammatory diseases of 
the CNS by the presence of chronic multifocal sclerotic lesions scattered throughout 
the brain and the spinal cord (Lassmann 1998).  These lesions represent the hallmark 
and endpoint of MScl pathology, and consist of localized areas characterized by 
ongoing demyelination; resulting in loss of myelin, relative axonal destruction and 
glial scar formation (gliosis) (Noseworthy, Lucchinetti et al. 2000).  
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Development	  of	  lesions	  –	  proposed	  disease	  mechanisms	  
The evolution of MScl lesions involves several steps: immune engagement, 
demyelination, acute inflammatory injury of axons and glial, limited remyelination, 
gliosis and neurodegeneration (Compston and Coles 2002; Bielekova and Martin 
2004). MScl is believed to be of autoimmune origin and initiated by activation of 
auto-reactive T cells against components of the oligodendrocyte-myelin unit. These T 
cells cross the blood-brain barrier (BBB) and gain access to the CNS (Trapp, Bo et al. 
1999; Bruck and Stadelmann 2003). Once inside the CNS, leukocytes and 
macrophages along with local glial cells, target specific areas of neurons and destroys 
myelin, causing relative axonal destruction and loss. At disease onset, inflammation is 
transient and remyelination occurs, however over time the pathological changes 
become dominated and eventually result in chronic neurodegeneration (Compston and 
Coles 2002).  
 
1.1.3	  Disease	  heterogeneity	  and	  clinical	  presentation	  
 
MScl is a complex disease, the combination of unpredictable clinical course and 
variations in mechanisms of myelin destruction across patients contribute to the 
heterogeneity of the disease (Lucchinetti, Bruck et al. 2000; Bruck and Stadelmann 
2003). Early events in the disease pathway of MScl are often clinically silent and may 
not result in any acute signs of the disease (Compston and Coles 2002), therefore 
neurological damage may be present before the first symptoms occur. The first 
indication of MScl is termed clinically isolated syndrome (CIS) of demyelination 
(Miller, Barkhof et al. 2005). Normally full recovery from the first episode of 
symptoms is observed. Over time, however, recovery from each relapse is incomplete 
and persistent symptoms accumulate. 60-80% of CIS patients convert to clinical 
definite MScl in the follow-up period (Miller, Chard et al. 2012). CIS and progression 
to MScl is unpredictable. The majority of MScl patients (85-90 %) have the relapsing 
remitting (RRMS) subtype, characterized by clearly defined relapses divided by 
periods of full recovery (Figure II). After a period of RRMS (normally 15-20 years) 
most patients progress into a secondary progressive (SPMS) disease course, in which 
the disease progressively worsens (Keegan and Noseworthy 2002). In the primary-
progressive (PPMS) type (affecting 10-15%), the disease is progressive in nature at 
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onset and disability increases over time without periods of improvements 
(Noseworthy, Lucchinetti et al. 2000).  
 
Figure II: Clinical subtypes of MScl. Based on the disease course of MScl, three main subtypes are 
recognized. A relapsing remitting subtype, affecting 80-85% of all MScl patients, that further could 
progress to secondary-progressive MScl. 10-20% of MScl patients have a progressive disease course 
from onset (PPMS). 
 
The median life expectancy of a MScl patient is around 30 years from disease onset 
(Compston and Coles 2008). Although there is no cure for MScl, early detection and 
subsequently early treatment will retard the long-term evolution of the disease.  
Treatment aims to slow down the disease progression, prevent axonal damage as well 
as reduce the frequency of relapses. The efficiency of treatment varies depending on 
the subgroup as well as progression of the disease (Compston and Coles 2008).  
 
1.1.4	  Current	  diagnosis	  of	  multiple	  sclerosis	  	  
Current diagnosis of MScl are mainly based on the McDonald (McDonald, Compston 
et al. 2001) and revised McDonald Criteria (Polman, Reingold et al. 2005), and relies 
in addition to disease history, on clinical examination supported by laboratory 
investigations. Magnetic resonance imaging (MRI) is performed to visualize lesions, 
detecting the demyelinating side of the disease.  Furthermore, CSF biochemistry 
measurements that include assessment of oligoclonal immunoglobulin G (IgG) bands 
are performed in order to detect the inflammatory side. The presence of oligoclonal 
IgG bands in CSF and further absence in blood serum, imply that immunoglobulin is 
produced in the CNS. MScl are considered clinically definite when neurological 
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dysfunction becomes “disseminated in time and space” (Noseworthy, Lucchinetti et 
al. 2000). The presented diagnostic findings are not disease specific for MScl, but 
could also indicate other inflammatory neurological diseases (OIND), which 
emphasizes the urgency of developing novel protein biomarkers that are exclusive for 
MScl.  
1.2	  Definition	  of	  biomarkers	  	  
The National Institutes of Health (NIH) officially defines a biomarker as "a 
characteristic that is objectively measured and evaluated as an indicator of normal 
biologic processes, pathogenic processes, or pharmacologic responses to a 
therapeutic intervention." In the presented study a biomarker refers to a protein 
measured in a body fluid whose concentration reflects the presence of MScl. Of 
particular interest are proteins with relevance to biochemical and physiological 
changes involved in the transformation from normal to diseased state. Due to the 
complexity and heterogeneity of MScl, there is probably no single protein or peptide 
that could serve as a biomarker for the disease in a clinically relevant way. It is 
doubtful that one single biomarker could reflect all ongoing pathological processes in 
addition to predict disease progression in all the disease subtypes. However, there is 
growing consensus that a set of disease specific proteins could be used in a biomarker 
panel (Ottervald, Franzen et al. 2010). Such a biomarker panel could be useful in the 
clinic to diagnose, monitor disease activity and predict disease progression (Rifai, 
Gillette et al. 2006).  
 
1.2.1	  Biomarker	  discovery	  in	  multiple	  sclerosis	  
 
Biomarker discovery strives to discover proteins that are either present, absent or of 
differential abundance in a large percentage of disease subjects and not in most 
subjects without the disease. In MScl, biomarker discovery is often based on studying 
protein abundance levels in CSF with the aim to identify proteins that differentiate 
between MScl and controls and that can potentially be used to diagnose, monitor 
clinical course, progression and treatment effects. In addition the biomarkers could 
add biological information that may provide insight into disease mechanisms of MScl.  
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Biomarker discovery can generally be performed in a wide range of biological 
material, such as body fluids and disease-affected tissue. In relations to MScl, lesions 
are of special interest as they are the primary location of disease specific activity and 
hallmarks of the disease. Unfortunately, due to inaccessible location, lesions are only 
biopsied post-mortem and could therefore be affected by processes that are not 
disease specific. For biomarker studies in living subjects, the body fluid most 
proximal to the MScl lesions represents a suitable choice. Cerebrospinal fluid (CSF) 
surrounds the CNS and fills the brain, the spinal cord as well as the subarachnoid 
space (Segal 1993). Thus CSF is in direct contact with the CNS and reflects in this 
way the biochemical state of the CNS under different physiological and pathological 
settings. Therefore, CSF is expected to reflect disease related alterations of its 
surrounding tissue (Harris and Sadiq 2009). Approximately 80% of the protein 
composition in CSF resides form blood, while the remaining 20% is derived directly 
from the CNS (Segal 1993; Tumani, Hartung et al. 2009). In this manner CSF is rich 
in brain specific proteins as well as it reflects the composition of blood plasma, 
although the concentration of proteins in CSF is lower. The crude protein 
concentration in CSF ranges from 0.2 to 0.8 mg/mL (0.3-1% of serum protein 
concentration) (Regeniter, Kuhle et al. 2009), though the concentration may vary due 
to individual variations such as overall health of the patient and biological variations 
concerning among others the Circadian rhythm (Nilsson, Stahlberg et al. 1992) and 
CSF flow rate (Reiber 1994). The CSF volume in a healthy human adult is 
approximately 150 mL (Smith, Johanson et al. 2004), and around 500 mL of CSF is 
produced each day. A typical volume of 10-15 mL are collected by lumbar puncture 
for laboratory investigations (Blennow, Fredman et al. 1993). 
 
The blood-brain barrier (BBB) and the blood-CSF barrier (BCSFB) separate CSF 
from the bloodstream (Smith, Johanson et al. 2004), and acts as gates for the 
exchange of proteins between the two body fluids. Thus, the protein composition of 
CSF is a combination of blood derived proteins as well as proteins produced locally 
by the CNS. Disease mechanism of MScl and other inflammatory neurological 
diseases are proposed to alter the protein composition of CSF, whereof BBB 
dysfunction could result in increased abundance of blood-derived proteins in CSF 
(Reiber 2001). The diffusion across the two barriers is under normal conditions size-
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dependent (Smith, Johanson et al. 2004). Larger blood derived proteins, like 
Apolipoprotein B and Hemoglobin are excluded and normally not present in CSF, 
hence these proteins could be used to check CSF for blood contamination (Zhang 
2007). Blood contamination of CSF may arise during lumbar puncture and even a 
small percentage of blood could dramatically alter the CSF proteome when analyzed 
(You, Gelfanova et al. 2005). 
 
1.2.2	  The	  Biomarker	  pipeline	  
 
Development of biomarkers is divided into four general phases, constituting of the 
discovery phase, the qualification phase, the verification phase and the validation 
phase (Rifai, Gillette et al. 2006). Biomarker discovery in MScl is performed in a 
relatively small number of well-characterized CSF samples. By comparing the 
proteomes of cases and controls one can detect differentially abundant proteins 
between the groups. In order to confirm the differential expression level, the 
candidate biomarkers are subjected to several additional quantification steps. The 
qualification phase is the first line of confirmation, in which biomarker candidates 
derived from the discovery phase are targeted for quantification in individual samples 
by use of alternative analytical methods. Verification of biomarker candidates is 
performed in larger patient cohorts by incorporating a boarder range of cases and 
controls. Biomarker validation is performed on the few candidate biomarkers that 
performed well in the verification phase, in which clinical assays like enzyme-linked 
immunosorbent assay (ELISA) are usually established. Finally, validated biomarkers 
may be selected for ‘commercialization’, in which research immunoassays are 
adapted for clinical testing (Rifai, Gillette et al. 2006).  
 
1.3	  Proteomics	  	  
 
The term proteome is a combination of “PROTEin” and “genOME” and refers to the 
total protein content expressed by a genome at a given time (Wilkins, Pasquali et al. 
1996). The proteome is the dynamic product of the genome, and due to various layers 
of protein processing; the proteome is prone to change in relations to different 
conditions. The proteome is the entire complement of proteins and their variants 
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produced by an organism, such as the human proteome, or of a limited system, such 
as the CSF proteome. Proteomics is the large-scale study of the proteome (Mallick 
and Kuster 2010), and involve technologies for identification and quantification of a 
large portion of the protein content, enabling the study of the complex and dynamic 
nature of proteins. Hence, proteomics analyses are performed in order to characterize 
proteomes as well as identify and quantify proteins of differential abundance by 
comparing distinct proteomes. For this purpose, mass spectrometry (MS) is a versatile 
technology available to analyze endogenous proteins in complex biological samples 
(Aebersold and Mann 2003). 
 
1.3.1	  Mass	  spectrometry-­‐based	  proteomics	  	  
 
The basic principle of mass spectrometry (MS) involves a technology that enables the 
measurement of mass-to-charge (m/z) ratio of ions in gas phase to determine the 
masses of peptides (Han, Aslanian et al. 2008). A mass spectrometer consists of an 
ion source, performing the ionization of peptides, a mass analyzer that separates the 
ions according to their m/z ratio and a detector that records the number of peptide ions 
at each m/z value (Aebersold and Mann 2003). 
 
Prior to being subjected to MS analysis, the peptides can be subjected to liquid 
chromatographic (LC) separation that is directly connected to the MS (LC-MS). The 
resulting chromatogram displays the eluting peptides as peaks with a given intensity 
and retention time. 
 
1.3.2	  Protein	  identification	  by	  use	  of	  mass	  spectrometry	  	  
Proteins are identified based on their corresponding peptides, either by the accurate 
mass or by the amino acid sequence of the peptides. Peptide mass fingerprinting 
(PMF) involves protein identification by searching the peptide masses measured by 
mass spectrometry against a database containing theoretical peptide masses (Gevaert 
and Vandekerckhove 2000). In order to obtain more detailed and reliable 
identification, tandem MS is applied. In tandem MS the peptide are further 
fragmented into its respective amino acids. 
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1.3.3	  Tandem	  mass	  spectrometry	  	  
In tandem MS the mass spectrometer measures the masses of all the peptides eluting 
at any given time from the chromatographic column, and subsequently select a 
number of peptide ions with the highest intensities for fragmentation. This is 
performed by allowing only ions of a particular mass through a collision cell, where 
they are provided with sufficient energy for the peptide bonds to break (de Hoog and 
Mann 2004). The resulting spectrum is called tandem mass spectrum (MS/MS). The 
tandem spectrum contains several adjacent fragments that spell out the amino acid 
sequence of the peptide in question (de Hoog and Mann 2004). The fragment masses 
are further compared to theoretical fragment masses calculated from all the peptides 
in protein databases to enable protein identification. Typical databases that can be 
used are SwissProt and UniProt, in which UniProt is unreviewed and automatically 
annotated, while the SwissProt database is reviewed and manually annotated with 
information extracted from the literature. There are several different search engines 
available, with Mascot being the most widely used. The in house developed software 
SearchGUI (Vaudel, Barsnes et al. 2011) combine the results from two search engines 
simultaneously, namely the Open Mass Spectrometry Search Algorithm (OMSSA) 
and X!Tandem. For visualization of the peptide and protein identifications, the in 
house developed software Peptide Shaker can be applied.   
 
1.3.4	  Sample	  processing	  prior	  mass	  spectrometry	  	  
Proteins of low abundance are of special interest in biomarker discovery, as these 
proteins are likely to be present as a result of ongoing disease specific processes. 
Detection of proteins of low concentration may be troublesome using MS, as they are 
often masked by the high concentration of more abundant proteins. In order to get 
broader proteome coverage, the proteome of a complex biological sample needs to be 
reduced. Fractionation strategies can be applied both on protein and peptide level. 
Separation on protein level includes separation using molecular weight (MW) cut-off 
filters, targeted protein depletion and separation by use of gel based techniques. 
Sample processing typically begins with depleting the sample of high abundant 
proteins. For this purpose several immuno-affinity depletion column has been 
introduced with antibodies targeting a selection of proteins. SDS-PAGE is among the 
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most used methods separating proteins according to size; hence enable identification 
and evaluation of proteins variants (isoforms, truncation and proteolytic products). 
The term gel based liquid chromatography mass spectrometry (GeLC-MS) combines 
the separation of proteins using SDS-PAGE followed by gel cutting, protein 
digestion, online reverse phase nano-LC separation, and MS analysis of the peptides 
from each gel band (Schirle, Heurtier et al. 2003). Before the protein mixture can be 
subjected to MS analysis, proteins are enzymatically digested into peptides. Trypsin is 
the most used protease for this purpose, and hydrolyzes peptide bonds at the carboxyl 
terminal side of lysine and arginine residues. On the peptide level, further 
fractionation can be applied, such as ion exchange chromatography (Strong Cation 
Exchange (SCX) and Strong Anion Exhange (SAX)). The term multidimensional 
protein identification technology (MudPIT) describes the use of multidimensional 
liquid chromatography prior MS analysis for protein identification (Washburn, 
Wolters et al. 2001). In general, the more separation and fractionation methods 
combined, the better coverage of the proteome is expected. 
 
1.4	  Quantitative	  proteomics	   	  
 
Quantitative proteomics aims to obtain quantitative information of the abundance of 
proteins and peptides in complex biological samples. Furthermore, this branch of 
proteomics aims to compare two or more distinct proteomes to identify proteins with 
altered abundance levels between the comparison partners (Bantscheff, Schirle et al. 
2007). Mass spectrometry-based proteomics enable both relative and absolute 
quantification of peptides and proteins (Aebersold and Mann 2003). Quantitative 
information can be obtained using non-targeted and targeted strategies. 
 
1.4.1	  Non-­‐targeted	  quantification	  strategies	  	  
Biomarker discovery studies aim to identify and quantify proteins that are of 
differential abundance between two or more physiological states. Discovery of such 
biomarker candidates are possible by comparing different proteomes. Relative 
quantitation, determination of a ratio between a proteins concentration in one sample 
versus that of another, can include labeling of the compared groups or a label-free 
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approach. Labeling strategies involves chemical incorporation of stable isotopes to 
label peptides in a sample, and are based on the assumption that a stable isotope 
labeled peptide have chemically identical properties to its endogenous counterpart, 
thus the peptides will behave identically during LC and MS analysis (Bantscheff, 
Schirle et al. 2007). Because the labeling reagent introduce a mass shift, the same 
peptide can be quantified separately in the same MS analysis, and their ratio represent 
the relative abundance of the corresponding peptides are obtained (Nesvizhskii, Vitek 
et al. 2007). Chemical incorporation of stable isotopes includes among others 
dimethyl labeling and iTRAQ. Stable isotope dimethyl labeling involve the use of 
formaldehyde to globally label the N-terminus and the amino group on lysine through 
reductive amination (Hsu, Huang et al. 2003). For relative quantification of stable 
isotope labeled peptides, MS and MS/MS information are obtained. The MS/MS 
information is used for protein identification, while the MS information is used for 
quantification. The software MaxQuant and Proteome Discoverer Daemon are 
commonly used for quantitative proteomics analysis.  
 
Label-free quantification uses no labeling of the different proteomes to be compared, 
instead comparison is performed by aligning individual sample LC-MS runs. The 
approach involves comparison of chromatographic and spectral analysis and is 
therefore dependent on similar conditions during LC and MS analysis of the samples. 
Strategies involve both measuring and comparing the mass spectrometric signal 
intensity of peptide precursor ions belonging to a specific protein (intensity based) 
(Mallick and Kuster 2010). Counting and comparing the number of fragment spectra, 
identifying peptides of a given protein (spectral count) (Mallick and Kuster 2010) or 
peptide abundance can be determined from the intensity of corresponding spectrum 
features identified by the mass spectrometer (feature based) (Nesvizhskii, Vitek et al. 
2007). The software MaxQuant, Spectrum Mill and Progenesis LC-MS are used for 
label-free relative quantification.  
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1.4.2	  Targeted	  quantification	  	  
 
Accurate	  Inclusion	  Mass	  Screening	  
Accurate Inclusion Mass Screening (AIMS) is a targeted MS method for detection of 
selected peptides derived from target proteins. Masses and charge state of unique 
peptides representing target proteins are incorporated into an including list. The MS is 
instructed to monitor the included peptides in each MS scan. MS/MS spectra for 
sequence confirmation are acquired when a peptide form the list is detected with both 
the correct mass and charge state (Jaffe, Keshishian et al. 2008).  
 
Selected	  reaction	  monitoring	  
Selected reaction monitoring (SRM) is a targeted MS method that enables 
quantification of a specific subset of proteins over a large number of samples, using 
peptides as surrogates for the target proteins (Gallien, Duriez et al. 2011). 
 
SRM is performed on a triple quadrupole (QQQ) mass spectrometer. In the triple 
quadrupole instrument two steps of mass filtering is performed in combination with 
collision-induced dissociation (CID). The instrument can be instructed to select and 
isolate the m/z value of the precursor peptide (peptide ion) in the first quadrupole 
(Q1). The peptide ion then enters the collision cell (Q2) and is fragmented. Predefined 
fragments (fragment ion) of the precursor peptide (fragment ion) are further 
monitored in the third quadrupole (Q3). The selected precursor/fragment ion pairs are 
referred to as transitions and are m/z settings for Q1 and Q3 (Lange, Picotti et al. 
2008). Thus, in SRM, the selected precursor to fragment ion “reaction” is monitored. 
The SRM methodology provides relative and absolute quantification of protein and 
peptide when appropriate standards are added.  
 
Stable isotope dilution (SID) in combination with SRM is the gold standard for 
absolute quantification (Gallien, Duriez et al. 2011). The absolute quantification 
(AQUA) approach (Kirkpatrick, Gerber et al. 2005) allows for both relative and 
absolute quantification. Absolute quantification (AQUA) of endogenous peptides 
requires comparison with internal standards of known concentrations. Stable isotope 
labeled internal standards (SISs) is synthetic homologs to the endogenous peptide 
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enriched with stable isotopes. Thus SISs have a higher mass and are referred to as 
‘heavy’ peptides, as appose to their endogenous counterpart recognized as ‘light’ 
peptides. In SID-SRM analysis, light and heavy transitions are analyzed for every 
precursor and fragment combination (Lange, Picotti et al. 2008). Dependent on if the 
concentration of the SIS is precisely determined; the absolute or relative concentration 
of the target peptide can be determined from the relative intensity of the light/heavy 
transitions.  
 
Figure III: Targeted protein quantification using stable isotope internal standards (SISs) and 
selected reaction monitoring (SRM). Targeted protein quantification is achieved by SRM on a triple 
quadrupole mass spectrometer (MS). The protein sample is digested and the peptide mixture is spiked 
in with stable isotope labeled internal standards (SISs). The peptide mixture is fractionated and ionized 
by liquid chromatography (LC) and electrospray ionization (ESI). The MS are instructed to target a list 
of peptides and fragments thereof, corresponding to the target proteins. In the first quadrupole (Q1) a 
specific peptide ion is selected. The peptide ion is fragmented by collision-induced dissociation (CID) 
in the second quadrupole (Q2). The corresponding fragment ion is filtered in the third quadrupole (Q3). 
The resulting peptide/fragment ion pairs are referred to as a transition and are highly specific for the 
given peptide.  
 
SRM data can be analyzed using the software Skyline or the software Analyst® and 
MultiQuant™, in which SISs and endogenous peptides are integrated and the most 
abundant transitions free of interference are used for quantification. The median SRM 
area ratio is used to quantify the abundance difference of proteins between two states. 
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Aims	  of	  the	  study	  	  	  
The overall aim of the presented study was to use mass spectrometry-based 
proteomics to study the human cerebrospinal fluid (CSF) proteome in search for 
biomarker candidates in multiple sclerosis. The presented study was divided into five 
different experiments. 
 
 
1. Biomarker discovery in multiple sclerosis 
The aim of the biomarker discovery experiment was to compare the neat and depleted 
CSF proteome of multiple sclerosis patients with controls by applying a CSF pooling 
strategy and label-free relative quantification of protein of differential abundance 
between the patient groups. 
 
2. Qualification of biomarker candidates using accurate inclusion mass 
screening  
The aim of the qualification experiment was to apply stable isotope dimethyl labeling 
and Accurate Inclusion Mass Screening (dimethyl-AIMS) for targeted quantification 
of the biomarker candidates in novel and individual CSF samples. 
 
3. Verification of biomarker candidates using selected reaction monitoring 
The aim of the verification experiment was use Stable Isotope Dilution Selected 
Reaction Monitoring (SID-SRM) for targeted quantification of discovered and 
literature-derived biomarker candidates in a larger patient and control cohort. 
 
4. Characterization of the normal human cerebrospinal fluid proteome 
The aim of the experiment was to do a comprehensive mapping of the CSF proteome, 
and to obtain an overview of the molecular weight distribution of certain biomarker 
candidates in CSF.  
 
5. Evaluation of size dependent differential abundance of CSF protein 
variants in multiple sclerosis 
The aim of the experiment was to obtain an abundance ratio between multiple 
sclerosis and controls for proteins present in both high and low molecular mass 
portions of the CSF proteome and to see if the two ratios of the same protein differed 
in multiple sclerosis.  
 	  	  	  	  	  	  
	  
	  
	  
Materials	  and	  methods	   16	  	  	  
16	  	  
2 Materials	  and	  methods	  	  All	  materials	  used	  in	  the	  following	  methods	  are	  listed	  in	  Table	  2.1.1	  and	  2.1.2.	  Unless	  stated	  otherwise,	  all	  additional	  chemicals	  were	  purchased	  from	  commercial	  sources	  and	  were	  of	  analytical	  grade.	  	  	  
Table	  2.1.1	  Chemicals	  	  
Supplier	   Chemical	   Quality	   Catalog	  number	  
Agilent	  Technologies	   Depletion	  Buffer	  A	   	   	  	   Depletion	  Buffer	  B	   	   	  
Amersham	  Biosciences	   Coomassie	  Brilliant	  Blue	  tablet	   	   	  	   DiThioTreitol	  (DTT)	   	   	  	   Tetramethylethylenediamine	  (TEMED)	   	   	  
Biorad	   30%	  Acrylamide/	  2.67%	  Bis	   	   	  	   Ammonium	  persulphate	  (APS)	   	   	  	   10%	  SDS	  solution	   	   	  
Fluka	  Analytical	  	  	   Acetonitrile	  (ACN)	  LC-­‐MS	  Chromosolv®	   MS	  grade	   	  	   Acetic	  acid	  (HAc)	   	   	  	   Formic	  acid	  (FA)	   MS	  grade	   	  	   Sodium	  cyanobromohydride	  (NaBH3CN)	   	   	  
Invitrogen,	  Life	  Technologies	   SeeBlue®	  Plus2	  Pre-­‐Staining	  Standard	  (1x)	   	   	  	   LDS	  Sample	  Buffer	  (4x)	  NuPage®	   	   	  	   4-­‐12%	  Bis-­‐Tris	  Gel	  NuPage®	   	   	  	   MES	  SDS	  Running	  Buffer	  (20x)	  NuPage®	   	   	  
Isotec™	   Formaldehyde-­‐13C-­‐d2	  (C13D2O)	   	   	  	   Formaldehyde-­‐h2	  (CH2O)	   	   	  	   Formaldehyd-­‐d2	  (CD2O)	   	   	  
Merck	   Glysine	   	   	  
Promega	   Trypsin	  Porcine	   	   V511A	  	   Trypsin	  Resuspension	  Buffer	  (acetic	  acid)	   	   V542A	  
Sigma-­‐Aldrich	   Urea	  Sigma	  Ultra	   	   	  
	   Methylamine	  40	  wt	  %	   	   	  
	   Iodoacetamide	  (IAA)	   	   	  
	   Trifluoroacetic	  acid	  (TFA)	   	   	  
	   Tris(hydroxymethyl)aminomethane	   	   	  
	   Calcium	  chloride	  (CaCl2)	  x	  2	  H2O	   	   	  
	   Ammonium	  bicarbonate	   	   	  
	   Water	  Chromosolv®	  Plus	  for	  HPLC	   MS	  grade	   	  
	   Metanol	  Chromosolv®	  (MeOH)	   	   	  
	   Triethylammonium	  biacrbonate	  (TEAB)	   	   	  
	   Sodium	  cyanoborodeuteride	  (NaBD3CN)	   	   	  
	   N-­‐octyl-­‐Beta-­‐D-­‐glucopyranoside	  (NOG)	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Table	  2.1.2	  Materials	  
Supplier	   Material	  
Agilent	  Technologies	   Spin	  filter,	  0.22	  μm	  
Millipore	   Ultra-­‐4	  Centrifugal	  Filter	  Unit	  (MWCO	  filters)	  
Waters	   Oasis®	  HLB	  μElution	  plate	  30	  μm	  
3M	  Empore™	   C18	  StageTip	  	   C8	  StageTip	  	  
Table	  2.1.3	  Kit	  
Supplier	   Kit	   Content	  
Invitrogen,	  Life	  Technologies	   Qubit™	  Quantification	  Kit	   Quant-­‐it™	  protein	  reagent	  	   	   Quant-­‐it™	  protein	  standard	  1	  	   	   Quant-­‐it™	  protein	  standard	  2	  	   	   Quant-­‐it™	  protein	  standard	  3	  	  
Table	  2.1.4	  Apparatus	  
Supplier	   Apparatus	  
Amersham	  Biosciences	  	   Electrophoresis	  Power	  Supply	  (EPS	  601)	  
	   Gel-­‐casting	  Pump	  
Biorad	   PROTEAN	  II	  xi	  vertical	  electrophoresis	  cells	  
	   Gradient	  Former	  model	  285	  
	   Gel	  casing	  plates	  and	  additional	  equipment	  	  
Eppendorf	   Concentrator	  5301	  
	   Centrifuge	  5810R	  
	   Thermomixer	  Comfort	  (Eppendorfmixer)	  
Invitrogen,	  Life	  Technologies	   Novex	  Mini-­‐Cell	  
Heraeus	   Biofuge	  Statos	  
	  
Table	  2.1.5	  Mass	  Spectrometers	  
Supplier	   Mass	  spectrometer	  
AB	  SCIEX	   Q-­‐Trap®	  4000	  LC-­‐MS/MS	  Systems	  
AB	  SCIEX	   Q-­‐Trap®	  5500	  LC-­‐MS/MS	  Systems	  
Thermo	  Scientific	   Orbitrap	  Velos	  Pro	  	  
Table	  2.1.6	  Liquid	  Chromatography	  system	  
Supplier	   	   	  
Dionex	  Ultimate	   3000RS	  nano-­‐LC	  system	  	   Pre-­‐column	  (Dionex,	  Acclaim	  PepMap	  Nano	  Trap	  column,	  C18,	  75μm	  i.d.	  x	  2	  cm,	  3	  μm)	  	  	   	   Analytical	  column	  (Dionex,	  Acclaim	  PepMap	  100	  RSLCnano	  column,	  75μm	  x	  15cm,	  C18,	  2	  μm)	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Table	  2.1.7	  Software	  
Supplier	   Software	  
AB	  SCIEX	   Analyst®	  1.5.1	  
AB	  SCIEX	   MultiQuant™	  2.1.2	  
Dionex	  Corporation	   Chromeleon™	  
Agilent	  Technologies	   Spectrum	  Mill	  
In	  house	  developed	   SearchGUI	  
In	  house	  developed	   Peptide	  Shaker	  
Thermo	  Scientific	   Proteome	  Discoverer	  
Thermo	  Scientific	   Proteome	  Discoverer	  Daemon	  	  
Stable isotope labeled internal standards (SISs) peptides used is listed in 
Supplementary Table 6.6 and 6.7. Due to the size and format an Additional appendix 
(Supplementary Tables 3.1B-3.5B) is available at a local computer (EIR server) at 
PROBE. 
 
2.1	  Clinical	  samples	  
 
The CSF samples used for CSF proteome characterization and biomarker discovery in 
multiple sclerosis (MScl) were obtained from four different locations: (I) Department 
of Neurology, Haukeland University Hospital, Bergen, Norway, (II) Neurology 
Department UCL, Université Catholique de Louvain, Brussels, Belgium, (III) 
Laboratory of Neuroimmunology, IRCCS, “C. Mondion Neurological Institute”, 
Pavia, Italy. All locations are part of the European BioMS-eu consortium for CSF 
biomarker research in multiple sclerosis (www.bioms.eu). Neurological normal CSF 
samples were collected from patients receiving spinal anesthesia prior to non-
neurological minor surgical investigations at the (IV) Department of Orthopedic 
surgery, Haukeland University Hospital, Bergen, Norway. These subjects were 
diagnosed as having no neurological diseases and were considered to have 
neurologically normal CSF.  
 
All CSF samples were collected according to the published consensus protocol for 
CSF collection and biobanking (Teunissen, Petzold et al. 2009). In brief, immediately 
after the CSF was collected by lumbar puncture, the CSF samples were centrifuged at 
450 x g for 5 minutes to discard cells and cell debris, and the supernatant was stored 
at -80 oC, until further sample processing. The protein concentrations in crude CSF 
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were measured using a QubitTM fluorometer (Invitrogen, Carlsbad, CA, USA) 
according to the instructions given by the vendor.  
 
2.1.1	  Patient	  selection	  
 
The multiple sclerosis (MScl) patients included in this study were initially diagnosed 
according to the revised criteria of McDonald (Polman, Reingold et al. 2005). Patients 
and controls were divided into six categories: (I) CIS: patients with CIS that had not 
developed clinically definite (CD) multiple sclerosis in the follow-up period. (II) CIS-
MS: patients with CD multiple sclerosis diagnosed as CIS at the time of lumbar 
puncture, (III) RRMS, (IV) controls with other neurological diseases (OND), (V) 
controls with other inflammatory neurological diseases (OIND), and (VI) spinal 
anesthesia subjects diagnosed as non-neurological (NN). All patient information is 
available in Supplementary Table 6.1-6.5. 
 
2.2	  Processing	  of	  CSF	  samples	  -­‐	  protein	  separation	  strategies	  
 
2.2.1	  Concentration	  and	  purification	  of	  CSF	  samples	  	  
 
Ultra-4 Centrifugal Filter Units (MWCO filters, Millipore, Billerica, MA, USA) 
containing Ultracel-3 membrane were used to desalt and concentrate CSF samples 
prior further processing. Salts and proteins less than 3 kDa was filtered out and 
thereby be excluded form the samples. 
 
The filters were washed with deionized water (Milli-Q water, Millipore, Billerica, 
MA, USA) and centrifuged at 3000 x g for 5 min at 4 °C (Centrifuge 5810R, 
Eppendorf AG, Hamburg, Germany). The total volume of CSF sample were added to 
the filters and centrifuged at 3000 x g for 30 min at 4 °C followed by an additional 
centrifugation round with 1 mL deionized water, and subsequent centrifugation until 
about the volume of 100 µL remained in the filter. Finally, the samples were 
concentrated to dryness by using a vacuum concentrator (Concentrator 5301 from 
Eppendorf AG, Hamburg, Germany). 
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Current MS-based proteomics is often biased towards abundant proteins, which may 
mask the detection of less abundant proteins. Therefore, the complexity of CSF 
proteomes was reduced prior to MS analysis. CSF samples were separated on protein 
level by performing two different strategies; immuno-affinity depletion of 14 
abundant proteins in CSF and SDS-PAGE strategies that separates proteins according 
to molecular size.  
 
2.2.2	  Immuno-­‐affinity	  depletion	  	  
 
A human Multiple Affinity Removal System (MARS HU-14) 4.6 mm x 50 mm LC 
column (Agilent Technologies, Santa Clara, CA, USA) was used for immuno-affinity 
depletion of 14 abundant proteins (albumin, IgG, antitrypsin, IgA, IgM, transferrin, 
haptoglobin, alpha-1-acid glycoprotein, alpha-2-macroglobulin, apolipoprotein A-I 
and A-II, fibrinogen, C3 and apoliprotein B).  According to the vendor, depletion of 
these 14 proteins accounts for approximately 94 % of the total protein amount.  
 
Dried and concentrated CSF samples were dissolved in 200 µL MARS Buffer A and 
further filtered through a 0.22 µm CTA filter (both from Agilent Technologies, Santa 
Clara, CA, USA) on 2000 x g at room temperature for 5 min, followed by injection 
onto the MARS column. The MARS column was connected to a Dionex Ultimate 
3000 nano-LC system (Thermo Scientific, Waltham, MA, USA) was equilibrated 
with MARS Buffer A.  
 
The gradient for the MARS column with dimensions 4.6 mm x 50 mm was as 
follows; for the first 9.5 minutes, 100 % Buffer A with a flow rate of 125 µL/min was 
used and the flow-through with depleted CSF proteins were collected between 3.2-13 
minutes. The bound fraction was collected from 15.5-21 minutes with 100 % MARS 
Buffer B with the flow of 1000 µL/min. The column was furthermore run in 100% 
MARS Buffer A to regenerate the column before the next sample was injected.  
 
The flow-through and protein depleted CSF was purified and concentrated with 3 kDa 
MWCO filters as described above, pre-rinsed with 0,1 % N-octyl-β-Dglycopyranoside 
(NOG) (Sigma-Aldrich, St.Louis, MO, USA) for increased protein recovery. Samples 
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were subsequently dried and concentrated at 30 °C by use of a centrifugal vacuum 
concentrator.  
 
2.2.3	  Separation	  of	  proteins	  using	  5-­‐15%	  gradient	  SDS-­‐PAGE	  
 
Gel casting 
In order to separate proteins according to size, a 20 cm 5-15% sodium dodecyl-
sulphate polyacrylamide gel electrophoresis (SDS-PAGE) gel was casted. The gel 
casting solutions were as follows; 5% acrylamide gel (28,5 mL Milli-Q water, 12,5 
mL 1.5 M Tris-Hcl (pH 8.8), 8.4 mL 30% Acrylamide/ 2.67 % Bis and 500 µL 10% 
SDS). The 15% acrylamide solution contained the same amount of 10% SDS and 5.6 
g Sucrose, in addition to 8.7 mL Milli-Q water, 12.5 mL 1.5 M Tris-HCl (pH 8.8), 25 
mL 30% Acrylamide /2.67 % Bis. The 5% and 15% solutions were made and 
transferred to a gradient former (Biorad, Hercules, CA, USA), followed by direct 
addition of 20 µL 10% ammonium persulfate (APS) and 8 µL 
Tetramethylethylenediamine (TEMED) (Amersham Biosciences, Piscataway, NJ, 
USA). The gradient solutions were added to the gel casing plates and left until 
polymerized.  Thereafter, the stacking gel was casted, by mixing 12.2 mL MilliQ 
water, 5.0mL 0.5M Tris-HCl (pH 6.8), 2.6 mL 30% Acrylamide / 2.67 % Bis and 200 
µL 10 % SDS followed by addition of 100µL 10 % APS and 20 µL TEMED to 
induce the polymerization.  
 
Loading and running SDS-PAGE gel 
CSF samples were reduced and alkylated prior to loading onto the gel. For reducing 
the CSF samples; 4 x LDS Sample Buffer (Invitrogen, Carlsbad, CA, USA) was 
diluted in Milli-Q water to 2 x, the reduction agent DTT (Amersham Biosciences, 
Piscataway, NJ, USA) was added to give a final concentration of 10 mM. The 
resulting sample solution was heated for 5 minutes at 100 °C and further cooled in 
room temperature before addition of the alkylating agent, iodoacetamide IAA (Sigma-
Aldrich, St. Louis, MO, USA). IAA was added to give a final concentration of 20 
mM, followed by incubation in the dark for 20 minutes.  Samples were loaded and the 
run at 60 V for 16 hours in 1 x electrode running buffer (25mM Tris base, 192 mM 
Glysine, 0.1% SDS diluted in milliQ water). 
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Gel staining 
After protein separation, the gel was stained with Coomassie Brilliant Blue 
(Amersham Biosciences, Piscataway, NJ, USA) in 30% methanol MeOH and 10% 
acetic acid for 2 hours and distained in 30% ethanol/ 10% acetic acid over night.  
 
2.2.4	  Separation	  of	  proteins	  using	  4-­‐12%	  NuPage®	  Bis-­‐Tris	  gel	  
 
For separation of proteins according to size over a short time period a 4-12 % Bis-Tris 
Gel, NuPage® (Invitrogen, Carlsbad, CA, USA)  (1.0mm x 10 wells) was used for 
SDS-PAGE. Reduced and alkylated CSF protein samples were loaded onto the wells 
and the gel was run at 200V for 20 minutes in MES-buffer (Invitrogen, Carlsbad, CA, 
USA). The gel was stained using Coomassie Brilliant Blue and distained in 30% 
ethanol/ 10% acetic acid as described above. 
 
2.3	  Digestion	  protocols	  
 
2.3.1	  In-­‐solution	  protein	  digestion	  using	  trypsin	  
 
The dried CSF sample was dissolved and gently mixed in 20 µL urea solution (480 
mg Urea, 1.7 µL 40 wt% methylamine in H2O and 630 µL dH2O). 20 µL trypsin 
buffer (0.61 g Tris and 15 mg CaCl2 x H2O) (all from Sigma-Aldrich) was added to 
each of the samples followed by incubation at room temperature with gentle shaking 
(300 rpm) in an Eppendorf Mixer. Each of the subsequent steps involved incubation 
periods of one hour (in the dark for IAA) after addition of 4 µL 100 mM DTT and 5 
µL 200 mM IAA (18.5 mg IAA in 500 µL dH2O) respectively. To avoid unwanted 
alkylation, 0,8 µL 100 mM DTT was added and samples where further incubated for 
10 minutes at room temperature. The samples were digested with Trypsin Porcine 
(Promega, Fitchburg, MO, USA) at a 1:50 trypsin to protein ratio, and incubated for 
15-17 hours (over night) in shaker at 37 °C with gentle shaking as above. To stop the 
reaction, 15 µL 10% Formic Acid (FA) (Fluka Analytical, Buchs, Switzerland) was 
added to each sample prior concentrating the CSF samples to dryness by use of a 
vacuum concentrator.  
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In-solution digestion protocol used at PROBE can be found at 
(http://www.uib.no/filearchive/in-solution-proteindigestion.pdf  
 
2.3.2	  In	  gel	  protein	  digestion	  using	  trypsin	  followed	  by	  extraction	  of	  liberated	  
peptides	  
 
Following protein separation using SDS-PAGE, the protein bands were excised from 
the gel, cut into 1mm cubes and transferred into individual Eppendorf tubes. 50-100 
µL of wash solution (250 µL Ambic, 4750µL Milli-Q water and 5 mL Acetonitrile 
(ACN)(MS grade)) was added to each sample to cover the gel cubes, and incubated at 
room temperature for 20 minutes in Eppendorf mixer. The supernatant was removed 
and the washing step was repeated several times until the gel pieces were properly de-
stained for Coomassie. 
 
The gel pieces were further dried in a vacuum concentrator at 30 °C. 
Trypsin (6 ng/ µL) Porcine was prepared by mixing 10 µL Trypsin Porcine (100 
ng/µL dissolved in 50 mM acetic acid) with 160 µL digestion buffer (1M Ambic and 
50 µL ACN to 900 µL deionized water), 20-40 µL was added to each sample and 
hydrated on ice for 30 minutes. The samples were further incubated for 16 h at 37 °C 
for protein digestion. The samples containing tryptic peptides were cooled in room 
temperature, spun down and the supernatant was transferred to a fresh tube. The 
remaining gel pieces were further extracted by addition of 30-50 µL 1% 
trifluoroacetic acid (TFA) (Sigma-Aldrich, St. Louis, MO, USA), and incubated in 
room temperature for 20 minutes with gentle shaking. The supernatant was pulled off 
and pooled with the first extraction. A final extraction with 30-50 µL 60% ACN/ 
0.1% TFA was pooled with the former extractions. The sample with extracted 
peptides was concentrated to 10-15 µL in a vacuum concentrator.  
 
The protocol for in-gel digestion is available at http://www.uib.no/filearchive/in-gel-
proteindigestion.pdf) 
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2.4	   Stable	   isotope	   dimethyl	   labeling	   and	   spike	   in	   of	   stable	   isotope	   labeled	  
internal	  standards	  	  
 
2.4.1	  Stable	  isotope	  dimethyl	  labeling	  	  
 
Stable isotope dimethyl labeling was performed as described in (Hsu, Huang et al. 
2003; Boersema, Aye et al. 2008). In brief, desalted CSF sample containing tryptic 
peptides were dissolved in 100 µL of 100 mM triethylammonium bicarbonate 
(TEAB) (Sigma-Aldrich, St.Louis, MO, USA). By addition of 10 µL 4% CH2O, 4% 
CD2O and 4% 13CD2O (all from Isotec™, Miamisburg, OH, USA), a reference pool 
was labeled light, whereas the individual control and case samples were labeled 
intermediate and heavy dimethyl label, respectively. The reducing agents were added 
as follows; 10 µL of 600 mM sodium cyanoborohydride (NaBH3CN) (Fluka 
Analytical, Buchs, Switzerland) was added to the light and intermediate labeled 
samples while 10 µL of 6 mM cyanoborodeuteride (NaBD3CN) (Isotec™, 
Miamisburg, OH) was added to the heavy labeled samples followed by 2 h incubation 
at room temperature with gentle shaking (350 rpm). The reaction was quenched with 
16 µL 1% ammonium solution. Finally, 8 µL 100% FA was added on ice as a 
subsequent quenching step and all three labeled samples (light, intermediate and 
heavy labeled) were pooled. The pooled samples was subjected to a second step of 
desalting and subsequently stored at -20 for further purification and mass 
spectrometric analysis.  
 
2.4.2	  Stable	  isotope	  labeled	  internal	  standards	  (SISs)	  
 
Stable Isotope Dilution Selected Reaction Monitoring (SID-SRM) allows for relative 
and accurate quantification of peptides and proteins, and involves spiking the samples 
with synthetic peptides incorporated with stable isotope, termed stable isotope labeled 
internal standards (SISs).  
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Selection	  and	  optimization	  of	  stable	  isotope	  labeled	  internal	  standards	  	  
Signature peptides for the biomarker candidate proteins were defined and their 
uniqueness examined with a BLAST search against all human proteins in the NCBI 
database. SISs incorporated with 13C and 15N corresponding to the signature peptides 
were purchased in crude quality from Thermo Scientific. Ideally, the SISs peptides 
should be added to the sample in amounts corresponding to the endogenous peptide 
levels, at least within one order of magnitude in concentration. For this purpose SISs 
were optimized by direct infusion on a Q-Trap 5500 (AB SCIEX, Framingham, MA, 
USA) and the three most intense fragments were included in the final SRM-assay. A 
standard curve was drawn to find the concentration where of the SIS peptide are in a 
1:1 relative level to the target endogenous peptide. Signature peptides were defined 
and SISs were optimized by others at PROBE. 
 
SISs were spiked into trypsin digested CSF samples prior desalting with C18 
StageTip (3M Empore™) as described in section 2.5.1. 
 
2.5	  Sample	  purification	  prior	  Mass	  spectrometry	  
 
Mass spectrometers are highly sensitive instruments; to avoid undesired signal 
interference and clogging of the pre-column sample clean up is performed prior 
injection into the instruments.  
 
2.5.1	  C18	  StageTip	  
 
Two layers of C18 StageTip (3M Empore™, Eagan, MN, USA) were packed into 
each pipette tip, serving as a column. The column was conditioned with 20 µL 60% 
ACN/ 0.1% FA, followed by 40 µL 0,1% FA. The concentrated CSF samples 
containing tryptic peptides were dissolved in 20 µL 0.1% FA and added to the 
column, followed running through the column with 40 µL 0.1% FA. The peptides 
were eluted by addition of 10 µL 60% ACN/ 0.1% FA followed by a last addition of 1 
µL 100% ACN to certify that every peptide was eluted. In order to exclude the high 
concentration of ACN the samples were dried in a vacuum concentrator. Followed by 
resolving in 0.5 µL 100% FA and 19.5 µL 3% ACN/ 5% FA. 
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2.5.2	  C8	  StageTip	  
 
The C8 filters (3M Empore™, Eagan, MN, USA) were conditioned with 10 µL 80% 
ACN/0.1% FA. Concentrated peptide samples were dissolved in 0.5 µL 100% FA and 
9.5 µL 0.1% FA and run through the filter. Followed by a second addition of 5 µL 
80% ACN/0.1% FA to ensure that all peptides were eluted form the column. 
Subsequently the samples were concentrated to dryness in a vacuum concentrator 
followed by a resuspension in 0.1% FA. 
 
2.5.3	  Oasis®	  HLB	  µElution	  Cleanup	  	  
 
Digested and concentrated CSF samples containing tryptic peptides were resuspended 
in 0.1% FA and desalted using reverse phase Oasis® HLB µElution Plate 30 µm 
(Waters, Milford, MA, USA). In brief, the plate were washed once with 500uL 80% 
ACN/0.1% FA, and subsequently washed twice with 500uL 0,1% FA. The dissolved 
samples were added to the wells on the µElution plate followed by washing three 
times with 500uL 0,1% FA. At this point the peptides are bound to the filters; to elute 
the bound peptides 100uL of 80% ACN/0.1% FA was added twice. The peptide 
samples were then transferred to fresh tubes and dried in a vacuum centrifuge and 
stored at -80oC until further analysis. The centrifuge speed was 200 x g for one minute 
for all steps, except the steps concerning sample addition, where 150 x g was used for 
three minutes. Centrifuge used for Oasis® HLB µElution cleanup was Biofuge Statos 
(Heraeus, Buckinghamshire, USA).  
 
2.6	  Development	  of	  SRM	  blood	  contamination	  assay	  
 
SISs corresponding to signature peptides for hemoglobin were purchased from 
Thermo Scientific in crude quality. Each peptide was manually optimized by direct 
infusion on a Q-Trap 4000 (AB SCIEX, Framingham, MA, USA). The three most 
intense transitions were selected and optimized with respect to collision energy (CE), 
declustering potential (DP) and collision cell exit potential (CXP).  
 
CSF test sample (i.e. pooled sample with CSF from multiple patients with various 
neurological conditions) were spiked with 1 µL blood/mL CSF. Each sample was 
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reduced, alkylated and trypsin digested (Section 2.3.1). SISs representing hemoglobin 
beta-1 was spiked into the CSF test samples at different concentration ranging from 
100 amol to 1 pmol, prior to desalting using C18 StageTip (Section 2.5.1). Each 
sample was subjected to LC SRM-MS analysis on a Dionex Ultimate NCS-3000 
nano-LC system coupled to a Q-Trap 4000. The amount of CSF loaded onto the 
column was kept constant (1µg CSF protein digest for each SISs dilution). The area 
ratio was calculated by dividing the area of SIS on the area of endogenous peptide, as 
the concentration of endogenous peptides was kept constant. The area ratio was 
plotted against the different SIS concentrations for generation of response curves. The 
approximate 1:1 ratios of the SISs and endogenous peptide were determined to 
generate a hemoglobin SRM-assay in order to detect hemoglobin in the CSF samples.  
 
The SRM data was analyzed using MultiQuant 2.1.1 (AB SCIEX, Framingham, MA, 
USA). SISs and endogenous CSF hemoglobin peptides were manually integrated and 
the data was evaluated in which transitions from the endogenous peptides with wrong 
retention time, poor integrations and signal-to-noise less than 3 were considered to be 
free of signal from hemoglobin e.g. free of blood contamination.  
 
2.7	  Mass	  spectrometric	  analysis	  	  
 
2.7.1	  Nano-­‐HPLC	  ESI-­‐LTQ	  Orbitrap	  Velos	  Pro	  mass	  spectrometry	  
 
For LC-MS/MS analysis desalted samples containing tryptic peptides was 
resuspended in 0.1 % FA and 0.5 µg/µL was injected onto a pre-column (Dionex, 
Acclaim PepMap Nano Trap column, C18, 75 µm i.d. x 2 cm, 3 µm) followed by 
separation on the analytical column (Dionex, Acclain PepMap100 RSLCnano 
column, 75 µm i.d. x 15cm, C18, 2 µm) using a Dionex Ultimate NCS-3500RS LC 
system coupled online to an Orbitrap Velos Pro (Thermo Scientific, Waltham, MA, 
USA) mass spectrometer. The LC run was of 90 minute (180 minute) duration and 
peptides were separated during a biphasic ACN gradient from two nanoflow UPLC 
pumps (flow rate of 280 nL /min) on the analytical column. Solvent A and B was 
0.1% FA (vol/vol) with 2% ACN and 90% ACN (vol/vol) respectively. The gradient 
composition was 8-38% B over 61.5 min, then 38-90% B over 3 minutes. Elution of 
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very hydrophobic peptides and conditioning of the column were performed during 5 
minutes isocratic elution with 90% B and 12 minutes isocratic elution with 5% B 
respectively.  
 
The eluting peptides were ionized in the electrospray and analyzed by the Orbitrap 
Velos Pro. The mass spectrometer was operated in the DDA-mode (data-dependent-
acquisition) to automatically switch between full MS scan in the Orbitrap and MS/MS 
acquisition in the ion trap. The instrument control was performed through Tune 2.6.0 
and Xcalibur 2.1. Survey full scan MS spectra (from m/z 300 to 2000) were acquired 
in the Orbitrap with resolution R=60,000 at m/z 400 (after accumulation to a target 
value of 1e6 in the linear ion trap with maximum allowed ion accumulation time 
500ms). The Top 7 (or 15) most intense eluting peptides above a ion threshold value 
of 1000 counts, and charge state 2 or higher, were sequentially isolated to a target 
value of 1e4 and fragmented in the high-pressure linear ion trap by low-energy CID 
(collision-induced-dissociation) with normalized collision energy of 35% and 
wideband-activation enabled. The maximum allowed accumulation time for CID was 
200 ms, the isolation width maintained at 2Da, activation q=0.25, and activation time 
of 10ms. The resulting fragment ions were scanned out in the low-pressure ion trap at 
normal scan rate, and recorded with the secondary electron multipliers. One MS/MS 
spectrum of precursor mass was allowed before dynamic exclusion for 30 sec. 
  
2.7.2	  Inclusion	  list	  dependent	  acquisition	  on	  the	  Orbitrap	  Velos	  Pro	  MS	  
 
The following parameters were used for inclusion list dependent acquisition on the 
Orbitrap Velos Pro mass spectrometer. A single Orbitrap MS scan from m/z 300 to 
1500 at resolution 60,000 was followed by four ion trap MS/MS scans at normal scan 
rate. The top four most abundant precursors from the inclusion list were targeted for 
MS/MS spectrum acquisition over the course of a 90-min experiment. Preview mode 
and charge state screening were enabled for selection of precursors. The m/z tolerance 
around targeted precursors was +/- 7.5 ppm. Dynamic exclusion was also enabled 
with a repeat count of 1.5 with a repeat duration of 6 s and exclusion duration of 30 s. 
Again the m/z tolerance for dynamic exclusion was 7.5 ppm. The intensity threshold 
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for triggering of a detected peak was set to 250, and collision energy was specified at 
40% for all inclusion list members. 
2.7.3	  Stable	  Isotope	  Dilution	  SRM-­‐MS	  analysis	  
 
For LC SRM-MS analysis a Q-Trap 5500 coupled to a Dionex Ultimate 3000RS 
nano-LC system was used. The concentrated samples were resuspended in 3% ACN/ 
5% FA, and 1 µL, corresponding to 1 µg CSF protein digest, was loaded onto the pre-
column (Dionex, Acclaim PepMap Nano Trap column, C18, 75 µm i.d. x 2 cm, 3 µm) 
followed by separation on a custom made column (Dionex, Acclain PepMap100 
RSLCnano column, 75 µm i.d. x 15 cm, C18, 2 µm). The LC analysis was of 70 
minute total duration with the following mobile phase: mobile phase A (0.1% FA) 
and mobile phase B (0.1% FA/ 90% ACN). The gradient used was as follows: 5-10 % 
B from 0-3 minutes, 10-45 % B from 3-45 minutes and 45-90% B from 45-45.5 
minutes, and hold at 90% B from 45.5-51.5 minutes. From 51.5-55 minutes ramp 
from 90-5% B and re-equilibrate column at 5% B from 55-70 minutes. The flow rate 
was 250 nL/min. The MS run time was 68 minutes. The peptides were analyzed using 
scheduled SRM, the target scan time was 1 second and the detection window 240 
seconds. Three transitions per peptide were monitored, whereof one transition per 
peptide was selected for accurate relative quantification analysis. Supplementary table 
6.6 and 6.7 displays the signature peptides, transitions used quantification, Q1 and Q3 
m/z values for the endogenous and SIS peptides and the collision energy used in the 
SRM analysis. 
 
2.8	  Bioinformatics	  
 
2.8.1	   Protein	   identification	   using	   SearchGUI/	   Peptide	   Shaker	   or	   Spectrum	  
Mill	  
 
The raw data files from MS analysis were search with both Sepctrum Mill (Agilent 
Technologies, Santa Clara, CA, USA) and SearchGUI and Peptide Shaker. 
(SearchGUI combine the search engines OMSSA and X!Tandem). The settings for 
protein identification were as follows; fixed and variable modifications were 
carbamidomethyaltion (c) and oxidation of methionine (m). Protease was trypsin, 
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Precursor Ion Mass Tolerance 10 ppm, Fragment Ion Mass tolerance 0.7 Da, fragment 
ion type 1: b and fragment ion type 2: y. Minimum precursor charge was 2, max 
missed cleavages was 2. Max precursor charge 4. The peptides and proteins identified 
by the search was autovalidated using the default settings and the false discovery rate 
(FDR) of less than 1%. The human Swissprot database (European Bioinformatics 
Institute (EBI) and the Swiss Institute of Bioinformatics (SIB)) was used.  
 
2.8.2	  Progenesis	  LC-­‐MS	  label-­‐free	  proteomics	  analysis	  
 
The software Progenesis LC-MS (Nonlinear Dynamics, Newcastle upon Tyne, UK) 
was used for label-free quantification and comparison of LC-MS proteomics data 
based on the volume of MS1 peaks. The MS1 features from the individual LC-MS 
runs were represents peptides and were presented in a 2D plot with m/z versus 
retention time. A feature is a peptide with its known retention time, m/z, isotopic 
distribution and volume (intensity). The intensity information was used to determine 
the relative quantitation of the peptides. The different runs were aligned based on 
retention time in order to compensate for any retention time drift between the runs. 
This enabled the detection of peptides with their differential abundance across the 
compared groups. Peptides were filtered and only peptides with a minimum fold 
change 1.5 between the compared groups and an analysis of variance (anova) p-value 
of less than 0.05 were selected for identification. The associated MS/MS spectra of 
the selected peptides were search against the human SwissProt database using 
SearchGUI, in combination with Peptide Shaker for protein identification as described 
above. 
 
2.8.3	  Generation	  of	  inclusion	  list	  for	  AIMS	  
 
In the AIMS approach, 17 proteins ranging from high to median abundance in CSF 
were targeted. For high abundant proteins five peptides per protein were selected 
while 10 peptides were targeted for lower abundant proteins. To generate the 
inclusion list, which is a key factor in targeted AIMS approach, the accession number 
of the proteins was searched in Expasy.org Bioinformatics Resource Portal using the 
database UniProtKB. From UniProtKB, the FASTA file for each protein was exported 
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into MSDigest (University of California, San Francisco), were in silico digestion was 
performed. The selected peptide criteria were as follows: proteins with max missed 
cleavages 0, constant modification carbamidomethyl (C), peptide mass (m/z) of 600.0 
to 4000.0. The MS-Digest generates the peptide sequence with monoisotopic mass of 
singly charge. These masses were further used to calculate the +2 and +3 mass values. 
The m/z of the peptide at a given charge is between 300 and 1500.  
 
The inclusion list for stable isotope dimethyl labeled peptides were generated by 
adding up the 28 Da (light labeled version), 32 Da (intermediate labeled version) and 
36 Da (heavy labeled version) to the original non-labeled mass of respective peptides 
as shown in Table 2.1.8. The final inclusion list of 354 selected peptides are available 
in Supplementary Table 3.2 B. 
 
Lysine 
(K) 
   Arginine 
(R) 
   
+2 L +28.0313 +3 L 18.6875 + 2 L +14.0156 + 3 L +9.3437 
+2 IM +32.0564 +3 IM 21.3709 + 2 IM +16.0282 +3 IM +10.6854 
+2 H +36.0756 +3 H 24.0504 + 2 H +18.0378 +3 H +12.0252 
 
Table 2.1.8: Generation of inclusion list for AIMS on stable isotope dimethyl 
labeled peptides. Dependent on if the peptide sequence ended with lysine (K) or 
arginine (R) the 2+ and 3+ mass values was calculated for light (L), intermediate (M) 
and heavy (H).  
 
2.8.4	  Analysis	  of	  dimethyl-­‐AIMS	  data	  using	  Proteome	  Discoverer	  Daemon	  
 
The raw data from the inclusion list dependent acquisition on the Orbitrap Velos Pro 
mass spectrometer was analyzed using Proteome Discoverer Daemon (Thermo 
Scientific, Waltham, MA, USA). The MS/MS data was used for protein identification, 
while the MS data was used for quantification.  
MS/MS spectra were extracted from the individual LC-MS/MS analysis and 
subsequently searched against the human SwissProt database. The MS/MS data were 
searched in Mascot in Proteome Discoverer in which the following parameters were 
used: 50 p.p.m., precursor mass tolerance, 0.5 Da fragment ion tolerance, no-missed 
cleavages, carbamidomethyl cysteine as fixed modification and oxidized methionine 
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as variable modifications. A dimethyl-based quantitation method was chosen in 
Proteome Discoverer, with mass precision requirement of 2 p.p.m. for consecutive 
precursor measurements. Taking into account the isotopic effect of deuterium, 1 min 
of retention time tolerance was applied for isotope pattern multiplets and allowed 
spectra with 2 missing channels to be quantified. After identification and 
quantification, the data was filtered according to very strict peptide acceptance 
criteria. These criteria included high confidence level and position rank 1 in Mascot 
search. 
 
2.8.5	  Analysis	  of	  SRM	  data	  by	  use	  of	  Analyst	  and	  MultiQuant	  
 
The mass spectrometric method SRM involves two stages of mass filtering. In the 
first mass filter, the target peptide (precursor ion) representing the target protein is 
selected and isolated followed by fragmentation. In the second mass filter, predefined 
fragments of the peptide ion (i.e. fragment ion) are monitored. The combination of 
precursor and the respective fragment ion is referred to as a transition and selected 
transitions for each peptide are used to monitor the target proteins across samples. For 
accurate relative quantification synthetic peptides, stable isotope–labeled internal 
standards (SISs) are introduced at known concentrations to each sample. The stable 
isotope labeled peptide will have identical properties as its endogenous counterpart, 
except the mass will be higher due to the synthetic peptide being enriched with stable 
isotopes. This mass increase allows the two peptides to be distinguished during 
analysis. Abundance of the target protein is determined by comparing the signal from 
the SIS peptide and the endogenous peptide in the sample. 
 
The raw data files from the SRM LC-MS were analyzed using the software Analyst® 
1.5.1 and MultiQuant™ 2.1.1 (both from AB SCIEX, Framingham, MA, USA).  
Analyst® is used to display the chromatograms, while MultiQuant™ enable peak 
integration. The selection of peaks is based on retention time. Transitions of where the 
endogenous peptide differed by more than 0.05 in retention time from the SIS peptide 
were excluded together with transitions displaying twin peaks. By performing peak 
integration the area ratio was obtained, which is the area under the curve of the 
endogenous peptide over the area under the SIS peptide. The area ratio is used to 
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quantify the differential abundance of target proteins between samples. In this 
manner, the area ratio was used to measure the differential abundance between the 
endogenous and SIS peptide. The average area ratio of transitions was calculated and 
used for quantification between samples.  	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3 Results	  
	  
Proteomics-­‐based	  biomarker	  discovery	  in	  multiple	  sclerosis	  	  
The schematic flow chart summarizes the main steps performed in the proteomics-
based biomarker discovery and verification studies presented in this section. In the 
screening phase we combined a CSF pooling strategy and a label-free relative 
quantitation approach to reveal proteins of differential abundance in MScl compared 
to controls. A selection of these proteins was further evaluated as biomarker 
candidates in MScl, by performing two independent quantification strategies. In the 
verification phase we performed biomarker qualification using a dimethyl-AIMS 
approach as an initial verification strategy to evaluate the potential of the proteins 
found in the screening phase as biomarkers candidates in MScl. A selection of 
potential biomarker candidates from the discovery study was supplemented with 
candidate proteins derived from the literature and subjected to biomarker verification 
using SID-SRM analysis.  	  
 
 
Figure 3.1.1: Biomarker discovery, qualification and verification in multiple sclerosis. The flow 
chart summarizes the different steps undertaken in the biomarker pipeline. In the first phase of the 
study (screening phase), a mass spectrometry-based proteomic approach (label-free quantification) was 
applied to pooled CSF samples form combined* MScl patients (n=16) and combined controls (n=15), 
in order to identify and quantify proteins of differential abundance (biomarker candidates) in CSF of 
MScl patients.  In the following phase (verification phase), a selection of the biomarker candidate 
proteins showing significant up-or down regulation in MScl, were chosen for qualification in 10 novel 
individual RRMS patients and 10 novel OIND as controls. Stable isotope dimethyl labeling of the 
samples was combined with the mass spectrometry-based method Accurate Inclusion Mass Screening 
(AIMS). Potential biomarker candidates were supplemented with biomarker candidates derived from 
the literature and targeted for verification in a larger patient cohort, by incorporation of broader range 
of patients (n=62) and controls (n=63). Biomarker verification was performed using Stable Isotope 
Dilution Selected Reaction Monitoring (SID-SRM) for accurate relative quantification. *Combined 
MScl (13 RRMS, 1 CIS-MS,1 SPMS and 1 PPMS) and combined controls (10 OIND and 5 OND).  
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3.1	   Discovery	   of	   differential	   abundant	   proteins	   in	   multiple	   sclerosis	   using	  
label-­‐free	  relative	  quantification	  	  
	  
The aim of the biomarker discovery was to compare the CSF proteome of combined 
multiple sclerosis (MScl) patients with the CSF proteome of other related disease 
groups as control, in order to identify and quantify proteins of differential abundance 
between the groups.  
3.1.1	  Included	  patients	  and	  analytical	  approach	  	  
All CSF samples (n=31) included in this study were considered free for blood 
contamination based on the criteria described in Section 2.6 in Materials and 
Methods. Each CSF sample was checked for blood contamination in a similar manner 
as described in the same section.  
 
By combining a CSF pooling strategy and a label-free quantification approach, 
relative quantitation of differentially abundant proteins between MScl (n=16) and 
controls (n=15) were obtained. All patient information are available in Supplementary 
Table 6.1. A total of six CSF pools were created, three MScl pools and three control 
pools. Each pool contained CSF from five different patients, whereof each patient 
contributed with 20 µg to a final amount of 100 µg per pool. One of the MScl pools 
consisted of six patients. The control groups consisted of patients with other 
inflammatory neurological diseases (OIND) and other neurological diseases (OND). 	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Figure 3.1.2: Biomarker discovery study design. The three MScl pools and three control pools were 
each processed on two different levels prior LC-MS/MS on an Orbitrap Velos Pro MS for label-free 
quantification. 95 % of the total protein amount of each CSF pool was depleted for 14 high abundant 
proteins, while the remaining 5% was trypsin digested directly. The portioning of each pool enabled 
biomarker discovery in both neat and depleted CSF. Data analysis was performed using Progenesis 
LC-MS. 
 
Each of the six CSF pools was processed in two different ways (as illustrated in 
Figure 3.2.1). In one approach, 95 % of the total sample was subjected to immuno-
affinity depletion prior trypsin digestion (Section 2.3.1 in Materials and Methods), 
while in the other approach the remaining 5 % of each sample was trypsin digested 
directly, without depletion (Section 2.2.2).  
 
Each of the 12 generated CSF samples, 6 neat CSF pools and 6 depleted CSF pools, 
each comprising approximately 5 µg protein, was trypsin digested (Section 2.3.1) and 
desalted (Section 2.5.3). Dried samples were resuspended in 0.1% FA and 0.5µg CSF 
protein digest from each of the 12 samples were subjected to LC-MS/MS using a 
Dionex Ultimate 3000RS nano-LC system coupled to an Orbitrap Velos Pro MS. The 
mass spectrometer automatically switched between full MS scans in the Orbitrap and 
MS/MS acquisition in the ion trap in a DDA-mode (data-dependent-acquisition). The 
LC analysis was of 90 minute duration and the top 7 most intense eluting peptides 
were sequentially isolated and fragmented in the high-pressure linear ion trap by CID 
(collision-induced-dissociation) as described in Section 2.7.1. 
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The data resulting from the MS analysis was further analyzed using the Progenesis 
LC-MS software (Section 2.8.2). After using this software the abundance of proteins 
identified from the three MScl pools was compared to the corresponding protein 
abundance from the control pools. The data obtained from neat CSF samples of MScl 
patients were compared with the corresponding data obtained from controls. The data 
from the depleted CSF proteomes were also compared between the two groups. In this 
manner the data obtained from the neat and depleted CSF samples was analyzed 
separately in two different experiments.  	  
3.1.2	  Protein	  identification	  and	  statistical	  analysis	  for	  relative	  quantification	  	  
Analyzing the protein identification in neat CSF from both patient groups gave 250 
protein identifications, while combining protein identification from MScl and controls 
in depleted CSF lead to identification of 410 proteins, hence 60% more proteins were 
identified after depleting the sample for the 14 high abundant CSF proteins. 
Supplementary Table 3.1 B displays proteins identified in neat and depleted CSF and 
their regulation level.  
 
Proteins were considered as increased in relative abundance if the fold change was 
>1.5 between MScl and control, with an anova p-value of 0.05 or lower. Based on the 
set criteria, a total of 65 proteins with different relative abundance were discovered 
(Supplemenary Tabel 3.1 B). Of the 65 differentially abundant proteins, 29 were 
significantly regulated only in neat CSF, while 28 proteins were significantly 
regulated only in depleted CSF (Supplementary Table 3.1 B). As shown in the Venn 
diagram in Figure 3.1.3, four proteins were regulated in both CSF fractions, and these 
proteins were: Ceruloplasmin, Complement C1q subcomponent subunit C, 
Complement factor B and Ectonucleotide pyrophosphatase. All four proteins showed 
the same level of regulation in both neat and depleted CSF (Supplementary Table 3.1 
B).  	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Figure 3.1.3: Proteins regulated in neat and depleted CSF. Of the 65 differentially abundant 
proteins, 29 were significantly regulated only in neat CSF, while 28 proteins were significantly 
regulated only in depleted CSF. Four	  proteins	  were	   found	   to	  be	   regulated	   in	  both	  CSF	   fractions:	  Ceruloplasmin,	   Complement	   C1q	   subcomponent	   subunit	   C,	   Complement	   factor	   B	   and	  Ectonucleotide	   pyrophosphatase.	   The	   proteins	   showed	   similar	   levels	   of	   regulation	   in	   neat	   and	  depleted	  CSF. 	  
3.1.3	  Biomarker	  candidate	  selection	  	  
Among the differentially abundant proteins discovered in neat CSF, six proteins were 
selected for further evaluation as biomarker candidates in MScl. While nine proteins 
derived from depleted CSF were selected. Ceruloplasmin and Ectonucleotide 
pyrophosphatase were discovered in both neat and depleted CSF. Hence, of the 65 
proteins, 17 potential biomarker candidates were selected for further qualification in 
individual CSF samples. Selection of candidate biomarkers was based on previous 
implications in the literature of their role in MScl or other neuro-inflammatory and 
neuro-degenerative processes and proteins showing high fold changes between MScl 
and controls. Table 3.1.1 summarizes the 17 selected biomarker candidates; the 
peptides used for quantification their abundance level in MScl. 	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Protein	   Acc.	  number	  
Peptides used for  
quantification 
Peptide	  
count	  
Spectral	  
count	  
Confidence	  
score	  
Anova	  
p-­‐value	  
Fold	  change	  
	  
Level	   in	  
MScl	  
Complement	  C3	   P01024	  
LSINTHPSQKPLSITVR 
IHWESASLLR 
ISLPESLKR 
FISLGEACKK 
SEETKENEGFTVTAEGK 
LDKACEPGVDYVYK 
SGQSEDRQPVPGQQMTLK 
AKDQLTCNKFDLK 
AAVYHHFISDGVRK 
9	   65	   992	   0.022	   -­‐2.2	   ê	  
Transthyretin	   P02766	   VLDAVRGSPAINVAVHVFR GPTGTGESKCPLMVK 
VLDAVRGSPAINVAVHVFRK 
3	   6	   359	   0.004	   2.3	   é 
Haptoglobin	   P00738	   LRTEGDGVYTLNNEK LRTEGDGVYTLNDKK 2	   8	   200	   0.028	   -­‐3.8	   ê	  
Alpha-­‐2-­‐
macroglobulin	   P01023	   TEVSSNHVLIYLDK YSDASDCHGEDSQAFCEK 2	   7	   200	   0.034	   -­‐1.7	   ê	  
Alpha-­‐1-­‐acid	  
glycoprotein	  1	   P02763	   SDVVYTDWKK  1	   6	   100	   0.039	   -­‐3.0	   ê	  
Alpha-­‐1-­‐
antitrypsin	   P01009	   GKWERPFEVK LGMFNIQHCKK 2	   10	   193	   0.006	   -­‐3.3	   ê 
Semaphorin-­‐7A	   O75326	   DCENYITLLER LQDVFLLPDPSGQWR 
YYLSCPMESR 
3	   19	   300	   0.024	   -­‐1.5	   ê	  
Osteopontin	   P10451	   KANDESNEHSDVIDSQELSK NDESNEHSDVIDSQELSK 2	   12	   300	   0.025	   1.6	   é	  
Amyloid	   beta	   A4	  
protein	   P05067	   MDVCETHLHWHTVAK 1	   4	   200	   0.040	   1.6	   é	  
Prostaglandin-­‐H2	  
D-­‐isomerase	   P41222	   MATLYSR 1	   6	   100	   0.002	   -­‐1.5	   ê	  
Neuroserpin	   Q99574	   MAVLYPQVIVDHPFFFLIR 1	   10	   100	   0.047	   1.7	   é	  
Cystatin-­‐C	   P01034	   QIVAGVNYFLDVELGR 1	   1	   100	   0.026	   3.7	   é	  
Pigment	  
epithelium-­‐
derived	  factor	  
P36955	   IAQLPLTGSMSIIPFLPLK EIPPEISILLLGVAH 2	   7	   200	   0.004	   1.7	   é	  
Zinc-­‐alpha-­‐2-­‐
glycoprotein	   P25311	   KSQPMGLWR AKAYLEEECPATLR 2	   9	   200	   0.034	   -­‐1.9	   ê	  
Hemopexin	   P02790	   GDKVWVYPPEKK DVRDYFMPCPGR QGHNSVFLIKGCK 
EWFWDLATGTMKER 
QGHNSVFLIKGCK 
5	   71	   799	   0.022	   -­‐1.9	   ê	  
Ceruloplasmin	   P00450	   NLASRPYTFHSHGITYYK  1	   5	   100	   0.043	   -­‐1.8	   ê 
Ectonucleotid	  
Pyrophosphatase	   Q13822	   VRDIEHLTSLDFFRK 1	   6	   180	   0.033	   2.0	   é 
 
Table 3.1.1: Selection of biomarker candidates identified and quantified with differential 
abundance levels in CSF pools of MScl patients versus controls. The table summarizes and lists the 
17 biomarker candidates selected for further evaluation in the biomarker pipeline. CSF pools of MScl 
and controls were processed in two levels in order to enhance protein coverage of the CSF proteome. 5 
% of each pool was directly trypsin digested, whereas the remaining 95 % were subjected to immuno-
affinity depletion of 14 high abundant proteins in CSF. The first six proteins in the table represent 
biomarker candidates detected in neat CSF, the next nine proteins were discovered in depleted CSF, 
whereas the two latter proteins represent biomarker candidates discovered in both neat and depleted 
CSF pools of MScl and control patients. All selected biomarker candidates showed significant 
differential CSF levels with the fold change exceeding 1.5 between MScl and controls and an anova p-
value less than 0.05.  	  
3.1.4	  Biomarker	  candidates	  discovered	  in	  neat	  CSF	  	  
Of the six biomarker candidates selected from the neat CSF, Haptoglobin, Alpha-1-
acid glycoprotein 1, Alpha-1-antitrypsin, Ceruloplasmin, Complement C3 and Alpha-
2-macroglobulin showed decreased CSF levels in MScl patients compared to controls, 
while Transthyretin and Ectonucleotid pyrophosphatase showed increased CSF levels 
in MScl. Figure 3.1.4 and 3.1.5 shows the abundance profiles of the selected proteins 
discovered in neat CSF.  
Results	   40	  	  	  
40	  	  
	  
Figure 3.1.4: Normalized abundance profiles of proteins showing significant decreased 
abundance in neat CSF of MScl patients. By using the software Progenesis LC-MS standardized 
normalized abundance profiles of the six CSF pools were obtained. In MScl there were significant 
decrease in CSF levels of six proteins: 1. Haptoglobin, 2. Alpha-1-acid glycoprotein 1, 3. Alpha-1-
antitrypsin, 4. Ceruloplasmin, 5. Complement C3 and 6. Alpha-2-macroglobulin.  	  
	  
Figure 3.1.5: Normalized abundance profiles of protein showing significant increased abundance 
in neat CSF of MScl patients. The CSF levels of Transthyretin and Ectonucleotid pyrophosphatase 
were significantly increased compared to CSF levels in controls. 1. Transthyretin and 2. Ectonucleotide 
pyrophosphatase.  
 
3.1.5	  Biomarker	  candidates	  discovered	  in	  depleted	  CSF	  	  
Depleting the samples of 14 abundant CSF proteins enabled the discovery of 32 
proteins with significant differential CSF levels in MScl patients compared to 
controls. Of these nine proteins were selected for further evaluation as biomarker 
candidates in MScl. Hemopexin, Semaphorin-7A, Zinc-alpha-2-glycoprotein and 
Prostaglandin-H2 D-isomerase were found with significant decreased CSF levels in 
MScl patients relative to the CSF levels in controls. Figure 3.1.6 and 3.1.7 shows the 
abundance profiles of the selected proteins discovered in depleted CSF.  	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Figure 3.1.6: Normalized abundance profile of proteins showing significant decreased abundance 
in depleted CSF of MScl patients. 1.  Hemopexin, 2. Semaphorin-7A, 3. Zinc-alpha-2-glycoprotein, 
4. Prostaglandin-H2 D-isomerase.  
 
Amyloid beta A4, Osteopontin, Cystatin-C, Pigment epithelium-derived factor and 
Neuroserpin were significantly increased in CSF levels of MScl patients. The 
abundance profiles of these five proteins are shown in figure 3.1.7. 	  
	  
Figure 3.1.7: Normalized abundance profiles of protein with significant increased abundance in 
depleted CSF of MScl patients. 1. Amyloid beta A4, 2.  Osteopontin, 3. Cystatin-C, 4. Pigment 
epithelium-derived factor and 5. Neuroserpin.  	  	  
Verification	  of	  differential	  abundance	  of	  biomarker	  candidates	  	  
The false discovery rate was expected to be rather high for the biomarker candidates 
identified in pooled CSF samples during the screening phase. Hence, a selection of 
the biomarker candidates derived from the discovery study was subjected to 
comprehensive evaluation in two independent verification studies; involving 
biomarker qualification and verification.  
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3.2	  Biomarker	  qualification	  using	  Accurate	  Inclusion	  Mass	  Screening	  	  
Qualification of biomarker candidates represents an initial verification process to 
assess the potential of the biomarker candidates in novel patients using an alternative 
quantification strategy. The 17 biomarker candidates derived from the discovery 
experiment (Table 3.1.1) were targeted for relative quantification to see if their 
differential abundance remained detectable between RRMS and controls when 
analyzing individual CSF samples. We applied stable isotope dimethyl labeling 
coupled to Accurate Inclusion Mass Screening (AIMS) for targeted quantification of 
17 proteins comparing individual CSF levels from 10 RRMS patients and 10 OIND.  	  
3.2.1	  Experimental	  design	  for	  dimethyl-­‐AIMS	  analysis	  	  
5 µg CSF each from 10 individual RRMS patients and 10 individual OIND patients 
were included in the qualification experiment. 5 µg of a global internal standard (GIS) 
was created by pooling the samples from RRMS patients (n=10) and OIND patients 
(n=10). All CSF protein samples were trypsin digested (Section 2.3.1), desalted 
(Section 2.5.3) and dried prior to labeling with dimethyl reagents. The GIS, OIND 
(controls) and RRMS (patients) were labeled with light-, intermediate- and heavy-
dimethyl reagent, respectively (Section 2.4.1). One portion of GIS (light version) was 
mixed with one sample from OIND (intermediate version) and one sample from 
RRMS (heavy version) generating 10 mixtures of samples. These resulting 10 pooled 
samples were desalted (Section 2.5.3), dried and resuspended in 0.1% FA prior 
analysis. 0.5 µg from each sample was analyzed by inclusion list dependent 
acquisition (AIMS) on the Orbitrap Velos Pro MS (Section 2.7.2). 
 
An inclusion list was generated comprising ten unique peptides for each low abundant 
biomarker candidate protein, and five unique peptides representing the high abundant 
proteins. The criteria for selected peptides were as follows; peptides were required to 
be unique to each of the proteins of interest, fully tryptic with no missed cleavages, 
and have no known or predicted post-translational modifications. In total 354 peptides 
were targeted for dimethyl-AIMS analysis of the 17 biomarker candidates. The +2 
and +3 charge state for each of the peptides was used to generate the inclusion for the 
targeted quantification analysis as described in Section 2.8.3. For AIMS analysis, m/z 
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values on the inclusion list (Supplementary Table 3.2 B) were monitored in each scan 
on a high mass resolution and mass accuracy MS system, and MS/MS spectra were 
acquired only when a peptide from the list was detected with both the correct mass 
and charge state. 
 
The dimethyl-AIMS data was analyzed using Proteome Discoverer Daemon (Thermo 
Scientific) as described in Section 2.8.4. The MS/MS spectra were extracted from the 
individual LC-MS/MS analysis and subsequently searched using Mascot against the 
human SwissProt database. The MS data was searched in Proteome Discoverer in 
which a dimethyl-based quantification method was chosen. Following identification 
and quantification, the data was filtered according to peptide acceptance criteria 
including high confidence level and position mark 1 in the Mascot search.	  	  	  
3.2.2	  Qualification	  of	  biomarker	  candidates	  	  
The peptide abundance of the biomarker candidates was monitored across 10 
experiments. In each experiment the peptide abundance of one RRMS patient (heavy 
dimethyl labeled) and one OIND patient (intermediate dimethyl labeled) was 
compared with the peptide abundance of the pooled GIS (light dimethyl labeled). A 
Student’s t-test p-value less than 0.05 was considered significant. 
 
As shown in Figure 3.2.1, the CSF levels of Alpha-1-acid glycoprotein 1, Alpha-2-
macroglobulin, Ceruloplasmin, Prostaglandin-H2 D-isomerase and Transthyretin 
obtained from the initial screening phase were all showing similar levels of regulation 
in individual CSF samples from novel patients. The differential abundance of 
Transtyretin was significant (p-value 0.007). The abundance levels of Cystatin C and 
Complement C3 contradicted the data obtained from the discovery experiment, 
however the abundance level of these two proteins obtained from the qualification 
experiment was supported by findings in the literature for Complement C3 (Stoop, 
Dekker et al. 2008) and Cystatin C (Qin, Qin et al. 2009), respectively. Hence, the 
first seven proteins shown in Figure 3.2.1 were further included in the list of 
biomarker candidates for further verification. 
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Protein	   Peptide	  used	  for	  quantification	   Median	   peptide	  
abundance	  
	  
RRMS	  	  	  	  	  	  	  	  	  	  	  	  	  OIND	  
Fold	  change	  
(RRMS/OIND)	  
Alpha-­‐1-­‐acid	  glycoprotein	  1	   TEDTIFLR 
EQLGEFYEALDCLR 
SDVVYTDWK	   0.68	   1.08	   -­‐1.6	  	  	  	  	  	  	  	  	  	  	  êRRMS	  Alpha-­‐2-­‐macroglobulin	   IAQWQSFQLEGGLK 
AIGYLNTGYQR 
FEVQVTVPK 
QFSFPLSSEPFQGSYK 
0.65	   1.05	   -­‐1.6	  	  	  	  	  	  	  	  	  	  	  êRRMS	  
Ceruloplasmin	   GAYPLSIEPIGVR 
ALYLQYTDETFR 
0.95	   1.09	   -­‐1.2	  	  	  	  	  	  	  	  	  	  	  êRRMS	  Cystatin	  C	   LVGGPMDASVEEEGVR 
ALDFAVGEYNK 
TQPNLDNCPFHDQPHLK 
0.52	   1.02	   -­‐2.0	  	  	  	  	  	  	  	  	  	  	  êRRMS	  
Complement	  C3	   EVVADSVWVDVK 1.19	   0.78	   1.5	  	  	  	  	  	  	  	  	  	  	  	  	  éRRMS	  Prostaglandin-­‐H2	   D-­‐isomerase	   MATLYSR AQGFTEDTIVFLPQTDK 
TMLLQPAGSLGSYSYR 
0.90	   1.34	   -­‐1.5	  	  	  	  	  	  	  	  	  	  	  êRRMS	  
Transthyretin	   TSESGELHGLTTEEEFVEGIYK 
GSPAINVAVHVFR 
YTIAALLSPYSYSTTAVVTNPK 
1.65	   0.95	   1.7	  	  	  	  	  	  	  	  	  	  	  	  	  êRRMS	  
Pigment	   epithelium-­‐derived	  factor	   lAAAVSNFGYDLYR TSLEDFYLDEER 1.22	   1.10	   1.1	  	  	  	  	  	  	  	  	  	  	  	  	  éRRMS	  Zinc-­‐alpha-­‐2-­‐glycoprotein	   YSLTYIYTGLSK 0.95	   1.50	   -­‐1.6	  	  	  	  	  	  	  	  	  	  	  êRRMS	  Amyloid	  beta	  A4	  protein	   AVIQHFQEK 
VESLEQEAANER 
0.85	   0.93	   -­‐1.1	  	  	  	  	  	  	  	  	  	  	  êRRMS	  Osteopontin	   ISHELDSASSEVN 0.91	   0.96	   -­‐1.1	  	  	  	  	  	  	  	  	  	  	  êRRMS	  
 
Table 3.2.1: Verification of differential abundance of biomarker candidate proteins. The table 
lists the seven proteins also included in the SID-SRM verification study, in addition an abundance ratio 
was obtained for the four latter proteins. All detectable peptides used for quantification are shown, in 
which the abundance level of the marked peptides are shown in Figure 3.2.1.  	  	  
SRM-assays for seven of the proteins listed in Table 3.2.1 were already developed, 
and these proteins were therefore included in the SID-SRM verification study. The 
differential abundance of Pigment epithelium-derived factor, Osteopontin, Zinc-
alpha-2-glycoprotein and Amyloid beta A4 protein obtained in the qualification study 
was not significant and as no SRM-assays were available for these proteins, they were 
discarded as biomarker candidates for further verification. 
 
3.3	  Verification	  of	  biomarker	  candidates	  using	  Selected	  Reaction	  Monitoring	  	  
Existing literature on proposed CSF biomarker candidates in MScl is extensive. 
However, many of the reported biomarker studies are performed in relatively small 
patient cohorts and lack further verification. Hence, in addition to eight biomarker 
candidates from the discovery experiment a selection of candidate proteins derived 
from the literature was included in a verification experiment using SID-SRM for 
targeted quantification. The literature-derived proteins were selected based on their 
reported differential abundance in MScl from various proteomics-based biomarker 
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discovery studies as well as indications in the literature of their role in MScl or other 
CNS inflammatory and degenerative processes.  	  
3.3.1	  Study	  design	  and	  conduction	  	  	  
The presented verification study included CSF samples from 125 patients in total. All 
patient information is available in Supplementary Table 6.3. CSF samples from 62 
CIS or multiple sclerosis patients and 63 controls were included. 13 CIS, 14 CIS-MS 
and 35 RRMS patients were compared with 32 OIND and 31 OND. Including CSF 
from patients diagnosed with CIS at the time of lumbar puncture, as well as CIS 
patients that had developed into clinical definite MScl in the follow-up period, 
enabled the evaluation of the biomarker candidates as potential early diagnostic 
markers in MScl. 
 
Stable Isotope Dilution-Selected Reaction Monitoring (SID-SRM) was applied for 
targeted verification of biomarker candidates, using stable isotope labeled internal 
standards (SISs) for targeted quantification. The SID-SRM-assays was developed by 
Ann Cathrine Kroksveen at PROBE. SID-SRM was used for verification of eight of 
the biomarker candidates from the discovery study; Alpha-1-acid glycoprotein 1, 
Alpha-2-macroglobulin, Ceruloplasmin, Complement C3, Prostaglandin H2 D-
isomerase, Transthyretin, Cystatin C and Neuroserpin. In addition, SRM-assays were 
developed for a selection of proteins that had been reported in the literature with 
differential CSF abundance levels in MScl patients in previous proteomics-based 
biomarker discovery studies. The differential abundance of the literature-derived 
proteins had been reported in various group comparisons. In this study we wanted to 
investigate if there were an abundance difference for these proteins between novel 
patient and control cohorts. Furthermore, we wanted to investigate if these proteins 
could have potential as early diagnostic markers for MScl. Literature derived 
biomarker candidates included, Alpha-1-antichymotrypsin, Apolipoprotein D, 
Clusterin, Contactin-1, Kallikrein-6, Leucine-rich alpha-2-glycoprotein, 
Secretogranin-1 and Secretogranin-2, Serotransferrin and Serum albumin. Taken 
together, 18 biomarker candidates were included in the verification study of which the 
endogenous peptides were detectable in neat CSF. Supplementary Table 6.7 displays 
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the proteins and their signature peptides. Supplementary Table 6.8 lists biomarker 
candidates included in this study with literature references.  
 
Signature peptides for each biomarker candidate protein were defined as previously 
explained (Section 2.4.2) and stable isotope labeled internal standards (SISs) 
corresponding to the signature peptides were purchased in crude quality from Thermo 
Scientific. Each CSF sample (n=125) comprising 10 µg protein was trypsin digested 
(Section 2.3.1) and identical amounts of SISs were spiked into each sample prior to 
desalting using C18 StageTips (Section 2.5.1). The amount of SIS used was similar to 
the amount of the endogenous form of the corresponding peptides determined in a 
CSF test sample used for SRM-assay development. Each sample was resuspended in 
3% ACN/ 5% FA and 1 µg CSF protein digest was analyzed by LC SRM-MS on a 
Dionex Ultimate 3000RS nano-LC system coupled to a Q-Trap 5500 as described in 
Section 2.7.3. The peptides were analyzed by scheduled SRM, with the target scan 
time set to 1 second and the detection window 240 seconds. Three transitions per 
peptide were monitored, whereof one transition per peptide was selected for accurate 
relative quantification analysis. Supplementary Table 6.7 displays the signature 
peptides, transitions used for quantification, Q1 and Q3 m/z values for the 
endogenous and SIS peptides and the collision energy used in the SRM analysis.  
 
Identical aliquots of a CSF test sample (i.e. pooled sample with CSF from multiple 
patients with various neurological conditions) were processed along side the patient 
CSF samples and spiked with SISs in the same way. These CSF test samples were 
used as quality controls of the sample processing and the analytical pipeline.  
  
The SRM data was analyzed by use of the software MultiQuant 2.1.1 (AB SCIEX). 
Transition sets of SISs and endogenous peptides were automatically integrated 
followed by manual evaluation of the data whereof transitions displaying retention 
time errors, interference or poor integration were excluded from further analysis 
(Section 2.8.5). The most abundant transition for each target peptide was used for 
quantification. The fold change between the groups was calculated using the median 
SRM area ratio from each group (e.g. median area ratio MScl over median area ratio 
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control) and a Student t-test was used to calculate the p-value. A p-value less than 
0.05 were considered significant.  
3.3.2	  SRM	  analysis	  of	  biomarker	  candidates	  from	  the	  discovery	  study	  	  
The significant decrease in abundance of Alpha-1-acid glycoprotein 1 found in the 
discovery experiment was verified by SRM as significant when comparing all MS 
patients (including CIS) and OIND controls. The fold change and respective p-value 
are listed in Table 3.3.1. Hence, comparison of the label-free and the SRM 
quantitative results indicates abundance decrease of this protein even in extended 
patient cohorts. Alpha-2-macroglobulin was significantly less abundant in CIS 
compared to OND. Cystatin C was the only protein with significant differential 
abundance in CIS compared to MScl. In addition, the CSF levels of Cystatin C was 
significant decreased comparing all MScl and OND, and CIS versus OND. Cystatin C 
and Neuroserpin were both showing significant increase in CSF level of MScl 
patients versus control in the discovery study, while in the verification study the 
differential expression of these proteins was decrease in CSF levels of CIS patients 
and OND. For Neuroserpin the significance was just outside the significance 
threshold (p-value of 0.0516).  	  
3.3.3	  SRM	  analysis	  of	  biomarker	  candidates	  selected	  from	  the	  literature	  	  
Significant abundance differences were found with SRM analysis for five of the ten 
proteins with reported differential abundance in MScl in the literature. Apolipoprotein 
D was significantly less abundant in RRMS versus OIND and OND. The CSF levels 
of Alpha-1-antichymotrypsin also were significant decreased in RRMS versus OIND, 
in addition to CIS compared with OIND. Combining all MScl in one comparison 
group gave the same significant decrease in abundance compared to OIND of the two 
proteins. Clusterin and Kallikrein-6 showed significant decrease in abundance level in 
all MScl when compared with OND. Kallikrein-6 also showed the same level of 
decrease in CIS versus OND. Tabel 3.3.3 and Figure 3.3.1 summarizes the results 
obtained in the biomarker verification study. Taken together significant differential 
abundance was found for seven of the 18 biomarker candidates using SID-SRM. 	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Comparison	   Protein	   Abundance	   Fold	  change	   P-­‐value	  Combined	  MScl	  vs.	  OIND	   Alpha-­‐1-­‐acid	  glycoprotein	  Alpha-­‐1-­‐antichymotrypsin	  Apolipoprotein	  D	   êMScl	  êMScl êMScl -­‐1.1	  -­‐1.2	  -­‐1.2	   0.0289	  0.0021	  0.0061	  Combined	  MScl	  vs.	  OND	   Apolipoprotein	  D	  Clusterin	  Kallikrein-­‐6	  Cystatin	  C	  
êMScl 
êMScl 
êMScl	  
êMScl 
-­‐1.2	  -­‐1.1	  -­‐1.3	  -­‐1.1	  
0.0027	  0.0499	  0.0179	  0.0196	  RRMS	  vs	  OIND	   Alpha-­‐1-­‐antichymotrypsin	  Apolipoprotein	  D	   êRRMS	  êRRMS	   -­‐1.5	  -­‐1.2	   0.0155	  0.0297	  RRMS	  vs	  OND	   Apolipoprotein	  D	   êRRMS	   -­‐1.2	   0.0179	  CIS-­‐MS	  VS	  OND	   Kallikrein-­‐6	   êCIS-­‐MS	   -­‐1.4	   0.0049	  CIS	  vs.	  OIND	   Alpha-­‐1-­‐antichymotrypsin	   êCIS	   -­‐1.6	   0.0023	  CIS	  vs.	  OND	   Alpha-­‐2-­‐macroglobulin	  Cystatin	  C	  Kallikrein-­‐6	  Secretogranin-­‐1	  
êCIS 
êCIS 
êCIS 
êCIS 
-­‐1.3	  -­‐1.6	  -­‐1.5	  -­‐1.3	  
0.0375	  0.0015	  0.0196	  0.0387	  CIS	  vs.	  MScl	   Cystatin	  C	   êCIS -­‐1.5	   0.0137	  OIND	  vs	  OND	   Cystatin	  C	  Kallikrein-­‐6	  Alpha-­‐1-­‐antichymotrypsin	   êOIND	  êOIND	  éOIND	   -­‐1.1	  -­‐1.4	  1.6	   0.0108	  0.0099	  0.0053	  
 
Table 3.3.1: Biomarker candidates showing significant abundance difference in the SID-SRM 
verification study. Fold change between compared groups was calculated from the median area ratio 
from SRM analysis and Student’s t-test p-value less than 0.05 was considered significant.  	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Figure 3.3.1: Proteins with significant differential CSF abundance in the SID-SRM analysis. 
Taken together, the presented proteins were in the SID-SRM analysis found to be differential abundant 
in several group comparisons. The respective group comparisons are shown in Table 3.3.1. The area 
ratios of the endogenous peptides used for quantification are plotted for each patient. 
 
 
 
A protein is given the status of a biomarker candidate if its differential abundance is 
constant between two states in independent patient material using independent 
analytical methods. The most interesting results from the biomarker discovery and 
verification study was the significant differential abundance of Alpha-1-acid 
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glycoprotein 1 and Cystatin C derived from the initial screening phase, and the 
literature-derived candidate proteins Kallikrein-6 and Apolipoprotein D.  	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3.4	  Characterization	  of	  the	  normal	  human	  CSF	  proteome	  	  
The schematic flow chart summarizes the main steps performed in the proteomics-
based characterization of the normal CSF proteome and subsequent evaluation of size 
dependent differential abundance of CSF proteins in MScl. The focus of the mapping 
experiment was to perform extensive fractionation of the CSF proteome on protein 
level to obtain a comprehensive set of reference proteins that could further be used for 
investigations in MScl. We applied high abundant protein removal followed by 
separation of CSF proteins according to size using gradient SDS-PAGE. The size 
distribution of proteins across the gel for a selection of biomarker candidates in MScl 
was further examined. We observed the same protein present in several mass areas on 
the gel representing far different masses then what the mass of the full-length protein 
would imply. This observation indicated the presence of several protein variants for 
this protein. These protein variants could be truncation products, splice variants, or 
post transitionally modified proteins. This information is important to reveal and will 
serve as a first step on the way to individually quantify different protein variants 
originating from the same gene.  
 
Figure 3.4.1: Characterization of the normal human CSF proteome and evaluation of biomarker 
protein variants in CSF of Mscl: The figure summarizes the different steps undertaken in 
characterization of the normal human CSF proteome and further evaluation of protein variants of 
biomarkers in CSF of MScl patients and controls. Characterization of the normal human CSF proteome 
was performed by use of CSF form non-neurological (NN) patients receiving spinal anesthesia prior 
minor surgery, to investigate size distribution of CSF proteins under normal conditions. The 
proteomics approach included extensive fractionation of the CSF proteome on protein level. We 
applied immuno-affinity depletion of 14 high abundant proteins in CSF followed by separating both the 
bound fraction and flow through fraction according to molecular mass using gradient SDS-PAGE. 
Based on the size distribution displayed by proteins in the normal CSF proteome, CSF from RRMS and 
OIND was subjected to evaluation of size dependent differential abundance of CSF protein variants. 
CSF from the two patient groups was separated according to size using SDS-PAGE. Following SDS-
PAGE separation, the gel was divided giving rise to a high and a low molecular mass fraction that were 
analyzed using label-free relative quantification aiming to obtain quantitative information of the 
proteins differential abundance in RRMS in high and low molecular mass fractions. 
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3.4.1	  Assessing	  blood	  contamination	  of	  the	  CSF	  samples	  	  
CSF could be contaminated with blood during lumbar puncture. In order to map the 
CSF proteome accurately, CSF samples contaminated with blood were avoided as 
these samples could introduce blood specific proteins to the CSF proteome. For the 
purpose of checking CSF for blood contamination a SID-SRM-assay was built with 
spike-in of stable isotope labeled internal standard (SIS) peptides representing 
hemoglobin, a blood specific protein. The hemoglobin SRM-assay was built together 
with Elise Aasebø (as described in Section 2.6).  
 
Each CSF sample form non-neurological patient (n=50) was checked individually for 
blood contamination using the developed hemoglobin SRM-assay. CSF samples had 
already been trypsin digested and desalted by others at PROBE. The CSF samples 
containing 19 µg tryptic peptides were spiked with hemoglobin beta-1 SIS peptides at 
approximately the same amount as the corresponding endogenous peptide in the blood 
contaminated CSF test sample (Section 2.6). Each sample was analyzed by LC SRM-
MS analysis on a Dionex Ultimate 3000RS nano-LC system coupled to a Q-Trap 
4000.  
 
The SRM data was analyzed using MultiQuant 2.1.1 (AB SCIEX). SISs and 
endogenous CSF hemoglobin beta-1 peptides were manually integrated and the data 
was evaluated in which transitions with wrong retention time, poor integrations and 
signal-to-noise less than 3 were considered to be free of signal from hemoglobin i.e. 
free of blood contamination. Of the 50 non-neurological CSF samples, 21 samples 
were considered as blood free as the hemoglobin levels were below the intensity 
threshold limit set for detection.  	  
3.4.2	  Experimental	  outline	  for	  mapping	  the	  normal	  CSF	  proteome	  	  	  
Each of the 21 samples without detectable blood contamination from non-
neurological subjects contributed with 500 µL to the total of 10.5 mL pooled CSF. 
The protein concentration of the pool was measured to be 0.399µg/µL. 3.5 mL 
corresponding to an amount of approximately 1.40 mg protein was used in this 
experiment. The CSF pool was concentrated, purified and subjected to immuno-
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affinity depletion of 14 high-abundant proteins (listed in Section 2.2.2). Immuno-
affinity based partitioning generated two CSF protein fractions, a bound fraction 
consisting of the 14 high abundant proteins and their potential associated proteins 
(referred to as the bound fraction), and a flow-through fraction enriched with the less 
abundant proteins in CSF (referred to as the flow-through fraction in Figure 3.4.2). 
Both fractions were reduced and alkylated (Section 2.2.3) followed by protein 
separation according to molecular mass using a 5-15% gradient SDS-PAGE gel 
(Section 2.2.3).  
 
 
Figure 3.4.2: Separation of bound and flow-through fractions of the CSF proteome according to 
molecular mass. The CSF proteome was extensively fractionated on protein level. First line 
fractionation involved separating the proteome into two distinct fractions: the immuno-affinity depleted 
high abundant proteins, and the low abundant fraction (flow through). Both fractions were separated 
according to molecular mass using gradient SDS-PAGE. Lane 1 shows the bound fraction, while lane 2 
displays the flow-through fraction. See Blue® Plus2 pre-stained protein standard was used as standard 
to get a certain impression of the size distribution during the separation, and is displayed in lane 3. 
Results	   55	  	  	  
55	  	  
Albumin accounts for about 70 % of the total protein concentration in CSF, this is clearly visualized on 
the gel whereof a large amount of protein are found at 67 kDa. 
 
Each of the excised bands in one of the two lanes on the gel represented a group of 
proteins at a specific molecular mass (Figure 3.4.2). A total of 83 fractions were 
generated, whereof 37 fractions were obtained from the depleted high abundant 
proteins and 46 from the flow through. Proteins were in gel digested using trypsin 
(Section 2.3.2) and peptides were desalted using C8 StageTips (Section 2.5.2). CSF 
protein digest from each individual fraction were resuspended in 0.1% FA prior to 
injection into the MS. A fraction of 0.5 µg was analyzed by LC-MS/MS for protein 
identification on an Orbitrap Velos Pro MS. The LC analysis was of 90 minutes 
duration and the top 15 most intense eluting peptides were sequentially isolated and 
fragmented in the high-pressure linear ion trap by CID (collision-induced-
dissociation). 
 
3.4.3	  Protein	  and	  peptide	  identifications	  	  
The identification of proteins and peptides from the MS/MS data was achieved using 
both the Spectrum Mill search engine and the SearchGUI algorithm searching against 
the human SwissProt database with FDR of less than 1% as a filtering threshold 
(Section 2.8.1). The software Peptide Shaker was used in combination with 
SearchGUI to display the peptide and protein identifications. A total of 18, 807 
distinct peptides were identified from all fractions, representing 1987 proteins 
(Protein and peptide information available in Supplementary Table 3.4 B). Among 
these 17, 824 peptides were identified in the low abundant fraction (flow through) 
(Lane 2, Figure 3.4.2) mapping to 1563 proteins. While 4001 peptides, mapping to 
424 protein entities were identified in the high abundant fraction (Lane 1, Figure 
3.4.2).  The Venn diagram in Figure 3.4.3 compares the peptide identification 
obtained from the high and the low abundant portioning of the CSF proteome.   	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Figure 3.4.3: Venn diagram representation of all peptides identified in CSF of non-neurological 
subjects.  Taken together, 18,807 peptides were identified. Extensive fractionation on protein level 
enabled a relative separation of low and high abundant CSF protein, leading to identification of 17,824 
peptides in the low abundant fraction and a total of 4001 peptide identifications were obtained in the 
high abundant fraction. By aligning the identified peptides in the different fractions, the total of 14,994 
peptides were exclusively identified among the low abundant proteins is CSF, whereas 1171 were 
exclusively identified as the high abundant fraction. Leading to 2831 peptides identified in both 
fractions.  
 
The number of proteins identified in the two mass fractions on the gel is shown in 
Figure 3.4.4. The high number of proteins identified from the bound fraction are 
likely to be present in this fraction due to unspecific binding either to the column 
beads or to the 14 proteins targeted by the depletion column. 
 
 	  
	  	  
Figure 3.4.4: Proteins identified in the normal CSF proteome. By combining all raw data files in 
one search using SearchGUI, the total of 1987 proteins were identified. Of these 1563 were identified 
in the low abundant fraction and 424 in the high abundant fraction. Comparing the protein 
identifications obtained from the two gel fractions showed 86 protein entities representing the 14 
proteins targeted by the depletion column. These 86 proteins were mostly isoforms of immunoglobulin.  
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3.4.4	  Protein	  distribution	  in	  the	  CSF	  proteome	  	  	  
One of the aims in this experiment was to target a selection of biomarker candidates 
and investigate their size distribution on the SDS-PAGE gel to reveal potential protein 
variants (isoforms, truncation products and potential proteolytic processed products). 
The identification data generated from Spectrum Mill (Section 2.8.1) enabled protein 
distribution information to be obtained from the individual gel sections. Of special 
interest was the protein distribution of the low abundant portion of the CSF proteome. 
Each of the excised bands, or gel sections, represented a group of proteins at a 
specific molecular mass. Proteins were expected to be present in gel sections 
corresponding to their mass. As shown in figure 3.4.5 over 700 proteins were only 
identified in one gel section. A few proteins were distributed along all 46 gel sections; 
in which a general trend showed proteins with high intensities to be present in more 
than one fraction. Proteins of high abundance were typically present in all fractions.  	  
	  
Figure 3.4.5: Protein distribution along the 46 fractions of low abundant proteins. The number of 
proteins is displayed on the x-axis, whereas the y-axis is displaying number of fractions. By processing 
each gel band as individual fractions, information of protein distribution was obtained. As showed in 
the distribution plot, over 700 proteins were observed in only one fraction. While a small number of 
proteins were identified in all 46 fractions.  
 
A selection of biomarker candidates was chosen for further investigation based on 
their protein size distribution the 46 sections, in which the proteins was identified in 
mass areas on the gel representing far different masses then what the full-length 
protein mass would imply. The protein distribution of the biomarker candidates 
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Alpha-1-acid glycoprotein 1, Apolipoprotein D and Cystatin C are shown in Figure 
3.4.6 A, B and C, respectively. We also chose to display the size distribution of 
Neuroserpin derived from the biomarker discovery study and the previously reported 
biomarker candidate Secretogranin-1 (Figure 3.4.6 D and E).  
	  
	   	   	   	   	   	  
	   	   	   	   	   	   	  Figure 3.4.6: Distribution of a selection of biomarker candidates in the 46 gel sections. 
	   	   	   	   	   	  By	  performing	   fractionation	   of	   the	  CSF	  proteome	  on	  protein	   level	  we	  were	   able	   to	   obtain	   size	  distribution	   information	   of	   a	   selection	   of	   biomarker	   candidates	   in	  MScl.	  The observation of the 
candidate protein present in several mass areas on the gel representing far different masses then what 
the mass of the full-length protein would imply indicated the presence of several protein variants for 
this protein.	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3.4.5	  Potential	  truncation	  products	  of	  the	  biomarker	  candidates	  	  
We hypothesized that the presence of truncation products of the proteins displayed in 
Figure 3.4.6 could be revealed by identifying non-tryptic peptides mapping to the 
proteins. By using the identification data generated from Spectrum Mill (Section 
2.8.1) we could obtain information of the peptides identified for the proteins in the 
individual gel sections. The peptide identification data of Cystatin C revealed 13 non-
tryptic peptides, whereas Secretogranin-1 revealed nine non-tryptic peptides. The 
presence of these peptides could further indicate the presence of several protein 
variants for each of these proteins in the normal CSF proteome. The identified non-
tryptic peptides are shown in the full-length sequence of Cystatin C and 
Secretogranin-1 in Figure 3.4.7. 
	  
	  	  
Cystatin	  C	  
MAGPLRAPLLLLAILAVALAVSPAAGSSPGKPPRLVGGPMDASVEEEGVRRALDFAVGEYNK
ASNDMYHSRALQVVRARKQIVAGVNYFLDVELGRTTCTKTQPNLDNCPFHDQPHLKRKAFC
SFQIYAVPWQGTMTLSKSTCQDA 	  
Secretogranin-­‐1	  
MQPTLLLSLLGAVGLAAVNSMPVDNRNHNEGMVTRCIIEVLSNALSKSSAPPITPECRQVLKT
SRKDVKDKETTENENTKFEVRLLRDPADASEAHESSSRGEAGAPGEEDIQGPTKADTEKWA
EGGGHSRERADEPQWSLYPSDSQVSEEVKTRHSEKSQREDEEEEEGENYQKGERGEDSS
EEKHLEEPGETQNAFLNERKQASAIKKEELVARSETHAAGHSQEKTHSREKSSQESGEETG
SQENHPQESKGQPRSQEESEEGEEDATSEVDKRRTRPRHHHGRSRPDRSSQGGSLPSEE
KGHPQEESEESNVSMASLGEKRDHHSTHYRASEEEPEYGEEIKGYPGVQAPEDLEWERYR
GRGSEEYRAPRPQSEESWDEEDKRNYPSLELDKMAHGYGEESEEERGLEPGKGRHHRGR
GGEPRAYFMSDTREEKRFLGEGHHRVQENQMDKARRHPQGAWKELDRNYLNYGEEGAP
GKWQQQGDLQDTKENREEARFQDKQYSSHHTAEKRKRLGELFNPYYDPLQWKSSHFERR
DNMNDNFLEGEEENELTLNEKNFFPEYNYDWWEKKPFSEDVNWGYEKRNLARVPKLDLKR
QYDRVAQLDQLLHYRKKSAEFPDFYDSEEPVSTHQEAENEKDRADQTVLTEDEKKELENLA
AMDLELQKIAEKFSQRG 
	  
Figure 3.4.7: Truncation products identified for the biomarker candidates Cystatin C and 
Secretogranin-1. By using the identification data generated from Spectrum Mill (Section 2.8.1) we 
could obtain information of non-tryptic peptides identified for the proteins in the individual gel 
sections. For Cystatin C 13 non-tryptic peptides were identified, while Secretogranin-1 revealed nine 
non-tryptic peptides.  
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3.5	   Evaluation	   of	   size	   dependent	   differential	   abundance	   of	   CSF	   protein	  
variants	  in	  Multiple	  Sclerosis	  	  
Based on the indications of presence of several protein variants for the biomarker 
candidate proteins in normal CSF, we wanted to investigate the findings in CSF of 
MScl. The aim of this experiment was to obtain quantitative information of protein 
abundance comparing high and low mass portions of the CSF proteome between 
RRMS and OIND. By separating CSF proteins of the two patient groups according to 
size using SDS-PAGE, the gel was divided into a high and a low mass fraction. 
Proteins present in both high and low mass areas on the gel were further targeted to 
obtain an abundance ratio between RRMS and controls and to investigate if these two 
ratios differed for the same protein.  
 
3.5.1	  Study	  design	  and	  analytical	  process	  	  
CSF from five RRMS and five OIND patients were included in the study, in which 
two pools were created, each comprising 10 µg CSF from five different patients in 
each group. Each CSF pool, containing a total of 50 µg protein, were reduced and 
alkylated (Section 2.2.3) and separated using a 4-12 % gradient NuPage® gel (Section 
2.2.4).  
	  	  
Figure 3.5.1: Separation of CSF proteins from RRMS and OIND patients. Lane 2 displays the 
separated CSF proteins of RRMS patients, while lane 4 displays the separated CSF proteins of OIND 
patients as controls. See Blue Plus2 pre-stained protein standard was used as standard (lane 1 and 5). 
The gel was cut at approximately 67 kDa under the band indicating the presence of serum albumin, 
resulting in a high and low mass fraction separation of CSF proteins from RRMS and OIND. The high 
and low mass fractions were further processed individually enabling the comparison of protein 
abundance in the two fractions between RRMS and OIND.   
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The gel was divided at 67 kDa resulting in a high and a low molecular mass 
separation of CSF proteins in RRMS and OIND. The four gel fractions were further 
processed individually. Each fraction was trypsin digestion (Section 2.3.2), desalted 
(Section 2.5.3), and dried samples were resuspended in 0.1 % FA. 1 µg CSF protein 
digest from each fraction was subjected to LC-MS/MS on a Dionex Ultimate 3000RS 
nano-LC system coupled online to an Orbitrap Velos Pro MS. The LC analysis was of 
180 minute duration for extensive peptide separation.  
 
The data resulting from the MS analysis were used for protein identification as well as 
label-free relative quantification analysis using Progenesis LC-MS (Section 2.8.2). By 
using this software the abundance of proteins identified in the high mass fraction of 
RRMS could be compared to the corresponding protein abundance in the high mass 
fraction of control. In the same manner protein abundance in low mass fractions could 
be compared across the two patient groups.  	  
3.5.2	  Protein	  identification	  	  
A total of 262 proteins were identified in the high mass fraction on the gel, while 292 
proteins were present in the low mass fraction. By comparing the two mass fractions, 
123 proteins were found to be present in both fractions (Figure 3.5.2). 
 
	  
 
Figure 3.5.2: Protein identifications in high and low molecular mass fractions. A total of 139 
proteins were identified in the high molecular mass fraction, while 296 proteins were identified in the 
low molecular mass fraction. By comparing the protein identifications in the two mass fractions, 123 
proteins were identified in both high and low mass areas on the gel. 
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3.5.3	   Quantitative	   comparison	   of	   protein	   identified	   in	   high	   and	   low	   mass	  
fractions	  in	  the	  CSF	  proteome	  of	  RRMS	  patients	  	  
A selection of the 123 proteins present in both mass areas on the gel were targeted for 
relative quantification between RRMS and controls, with the aim to determine if the 
ratio of the protein present in the two mass fractions differed for the same protein 
between the two patient groups. The selection of proteins to examine was based on 
the proteins showing interesting protein distribution (Figure 3.4.6). 
	  
Protein	   Acc.	  number	  
Peptides used for 
quantification 
Peptide	  
count	  
Spectral	  
count	  
Confidence	  
score	  
High	  mass	  
FC	  
(RRMS/OIND)	  
Low	  mass	  	  
FC	  	  
(RRMS/OIND)	  
Serum	  albumin	   P02768	   114 114	   1526	   15801	   1.0	  	  é	   1.1	  	  é	  
Alpha-­‐1-­‐acid	  
glycoprotein	  1	   P02763	   8 11	   52	   1478	   -­‐1.3	  ê	   -­‐2.6	  ê	  
Apolipoprotein	  D	   P05090	   6 6	   17	   593	   1.2	  	  	  é	   -­‐1.3	  ê	  
Neuroserpin	   Q99574	   1 1	   2	   100	   -­‐1.5	  	  ê	   -­‐1.8	  ê	  
Cystatin-­‐C	   P01034	   4 4	   6	   399	   2.1	  	  	  	  é	   -­‐1.5	  ê	  
Secretogranin-­‐1	   P05060	   4 4	   5	   399	   11.8	  	  é	   -­‐1.5	  ê	  
	  
Table	  3.5.1:	  A	  selection	  of	  proteins	  identified	  in	  both	  high	  and	  low	  mass	  fractions.	  CSF	  from	  RRMS	   patients	   and	   OIND	   were	   separated	   according	   to	   size	   using	   SDS-­‐PAGE	   and	   the	   proteins	  identified	   in	   both	   high	   and	   low	   mass	   areas	   on	   the	   gel	   was	   subjected	   to	   label-­‐free	   relative	  quantification	   comparing	   protein	   abundance	   between	   the	   two	   patient	   groups.	   By	   using	   the	  software	   Progenesis	   LC-­‐MS	   the	   fold	   change	   between	   RRMS	   and	   controls	   were	   obtained	   for	  proteins	  present	  in	  both	  high	  and	  low	  mass	  areas	  on	  the	  gel.	  
	  	  
Serum albumin was found to be equally regulated in the two mass fractions. Similar 
regulation levels were also shown for Alpha-1-acid glycoprotein 1 and Neuroserpin 
being less abundant in RRMS compared to OIND in both mass fractions (Table 
3.5.1). Cystatin C, Apolipoprotein D and Secretogranin-1 were among the oppositely 
regulated proteins. As displayed in Table 3.5.1, these proteins showed increased 
abundance in RRMS compared to OIND in the high mass fraction, while in the low 
mass fraction the proteins showed opposite regulation levels. The largest difference 
was observed for Secretogranin-1 that had an 11.8 fold increase in CSF levels in 
RRMS compared to OIND in the high mass fraction. While in the low mass fraction, 
the protein was decreased in RRMS (with a fold change of -1.5). Hence, 
Secretogranin-1 showed a 10 time higher intensity in the low mass fraction compared 
to the low intensity in the high mass fraction, as displayed in Figure 3.5.3. 
Distribution of Secretogranin-1 in the normal CSF proteome indicated the protein to 
be present in 40 fractions (Figure 3.4.6 E). The full-length protein of Secretogranin-1 
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has the molecular mass of 78 kDa, hence was expected to be present in fractions 
above 67 kDa.  	  
	   Peptide	  
Quant	  
Peptides	   Fold	  change	  
(RRMS/OIND)	  
RRMS	   Normalized	  
abundance	  
RRMS	  
Normalized	  
abundance	  
OIND	  
High	   mass	  
fraction	  
4	   SQREDEEEEEGENYQK 
HLEEPGETQNAFLNER 
GEAGAPGEEDIQGPTK 
CIIEVLSNALSK 
11.8	   é	   124937	   10605	  
Low	   mass	  
fraction	  
6	   NYPSLELDK 
HLEEPGETQNAFLNER 
NYLNYGEEGAPGK 
CIIEVLSNALSK 
GEAGAPGEEDIQGPTK 
ASEEEPEYGEEIK 
-­‐1.5	   ê 	   1231557	   1864980	  
 
Table 3.5.2: CSF abundance of Secretogranin-1 in high and low mass fractions on the gel. The 
data obtained from label-free relative quantification approach using the software Progenesis LC-MS 
enabled the abundance of peptides identified in the high mass fraction of RRMS to be compared with 
the abundance of peptides mapping to Secretogranin-1 in the high mass fraction of OIND. The same 
comparison was performed for peptides identified in the low mass fraction. Shown in the table are 
peptide used for quantification of Secretogranin-1 in the two mass areas on the gel, fold changes 
between RRMS and OIND, regulation level in RRMS, and normalized protein abundance intensity are 
shown.  
 
Figure 3.5.3: Secretogranin-1 show opposite regulation levels in high and low molecular mass 
fractions of CSF from RRMS patients. Normalized abundance levels of the Secretogranin-1 are 
shown. Secretogranin-1 showed a 10 time higher intensity in the low mass fraction compared to the 
high mass fraction. 
 
Secretogranin-1 is a biomarker candidate previously been reported with differential 
abundance levels in MScl (Kroksveen 2012). Secretogranin-1 is a proprotein known 
to be proteolytically processed in vivo giving rise to biologically active peptide 
fragments (Benjannet, Leduc et al. 1987). The CSF concentrations of peptides derived 
from the protein have been reported as decreased in MScl (Mattsson, Ruetschi et al. 
2007). The preliminary results of this study indicate differential CSF levels of 
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Secretogranin-1 full-length protein and protein variants in RRMS compared to OIND. 
Further studies could be done to investigate the involvement of peptide fragments 
derived from Secretogranin-1 in MScl pathogenesis. 
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4 Discussion	  	  
In this study we used mass spectrometry-based proteomics to study the cerebrospinal 
fluid proteome and revealed proteins involved in the pathogenesis of multiple 
sclerosis that could serve as biomarker candidates for the disease.  
 
In the following sections, the quantification strategies used for biomarker discovery 
and verification are discussed in light of the observed abundance variations of the 
biomarker candidates across the different analytical approaches. Two main challenges 
in mass spectrometry-based proteomics are addressed: the complexity and dynamic 
range of protein composition in CSF, and the extent of biological variations. The four 
most interesting biomarker candidates from our studies are discussed in view of their 
pathological roles in MScl. Finally, the results obtained from the mapping experiment 
are discussed along with the further analysis that revealed opposite regulation level of 
the biomarker candidate Secretogranin-1 in high and low mass fractions of the CSF 
proteome. This section starts with a discussion around the patient and control groups.  
 
4.1	  Patient	  selection	  and	  controls	  	  
80-85 % of all MScl patients experience a relapsing-remitting disease course; hence 
biomarker discovery in RRMS patient represents a starting point for detecting 
significantly differential abundant proteins in clinical definite stages of the disease. 
Controls with OIND and OND are chosen over healthy controls. As MScl is 
considered to be an inflammatory disease involving neurodegenerative events, the use 
of other inflammatory neurological diseases (OIND) as controls minimize the risk of 
detecting general biomarkers for these pathological processes. The use of other 
neurological diseases (OND) represent an additional control layer, which further 
lowers the risk of identifying general markers for neurological diseases. In the SRM 
verification study we further included patients diagnosed with CIS at the time of 
lumbar puncture, as well as CIS patients that had developed into MScl, to enable the 
detection of abundance changes that take place at an early disease stage. Such 
proteins would potentially have great value as early diagnostic biomarkers for MScl. 
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4.2	  Biomarker	  discovery	  in	  multiple	  sclerosis	  
 
In the biomarker discovery we applied a CSF pooling strategy and a label-free relative 
quantification approach to compare neat and depleted CSF proteomes between MScl 
patients and controls. The dynamic range in protein concentration in CSF is expected 
to be approximately nine orders of magnitude (Zhang 2007), while proteomics 
methods based on mass spectrometry have a detection limit within four or five orders 
of magnitude within a single mass spectrum (Rifai, Gillette et al. 2006). Hence, there 
is an imbalance between the complex CSF proteome and the MS instrumentation used 
for analysis, in which high abundant proteins are more likely to be detected, thus 
hampering the detection of lower abundant proteins. To reduce this problem, we 
chose high abundant protein depletion as a strategy to allow for broader proteome 
coverage. Each MScl and control pools were processed on two levels, enabling 
biomarker discovery in neat and depleted CSF (Section 3.1). The aim with the neat 
CSF strategy was to quantify high abundant proteins, while the depletion strategy was 
included to cover more of the proteome in the comparison, and this was indeed also 
observed from the result, with 60% more proteins identified after depletion. We 
discovered 65 proteins of differential abundance, in which only the 17 most promising 
were selected as biomarker candidates in MScl for further verification (Section 3.2 
and 3.3). Some of the discovered biomarker candidates may be false positives; 
proteins that upon further evaluation are not differentially abundant. Due to limited 
number of patients included and the pooling strategy applied, and only three pools 
each of MScl and controls, the false discovery rate was expected to be rather high at 
this point of the biomarker pipeline. The pooling strategy was chosen to reduce the 
biological variance and at the same time keep the number of samples to be analyzed 
by MS relatively low.  
 
4.3	  The	  dimethyl-­‐AIMS	  approach	  for	  confirmation	  of	  differential	  abundance	  	  	  
All phases that followed discovery in the biomarker pipeline replaced unbiased 
screening with targeted quantification approaches. We applied stable isotope dimethyl 
labeling coupled to the AIMS approach for targeted quantification of the 17 selected 
biomarker candidates from the screening phase. The dimethyl-AIMS approach was 
developed by Thin Thin Aye at PROBE, and as far as we know this is the first report 
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of this approach applied to biomarker qualification. We managed to identify 15 of the 
proteins in neat and individual CSF samples from 10 RRMS patients and 10 controls 
as described in Section 3.2. However we were not able to obtain an abundance ratio 
for all peptides in all experiments. This lack of quantification appears to be caused by 
the software used for analyzing the data, and could be improved if new software 
becomes available. The ten experiments could also have been analyzed by three 
technical replicates to improve detection and quantification confidence. 
 
The biomarker qualification process resulted in 11 quantified proteins (Section 3.2). 
The only protein found to be significantly differential abundant was Transthyretin. As 
SID-SRM assays were already available for seven of the 11 quantified proteins, these 
proteins were also included in the SRM verification, even if not proven to have 
significant abundance changes from the qualification experiment. In the qualification 
study, the peptide abundance profiles obtained from these seven proteins were similar 
to that obtained from the screening phase, with exception of Complement C3 and 
Cystatin C contradicting the abundance levels of the two proteins. In the literature, 
increased abundance have been reported for Complement C3 (Stoop, Dekker et al. 
2008), while decreased CSF abundance of Cystatin C have been reported in RRMS 
(Qin, Qin et al. 2009), supporting the results obtained from the dimethyl-AIMS 
analysis. The reason for not confirming more than one of the discovery findings as 
significant during the qualification study could be due to the limited number of 
samples included as discussed above in Section 4.2 and due to biological variations as 
discussed below in Section 4.5. 
 
4.4	  Selected	  reaction	  monitoring	  for	  biomarker	  verification	  	  
SID-SRM applied to biomarker verification allows for simultaneously targeting 
quantification of a set of peptides representing target proteins in larger patient cohorts. 
SID-SRM increases the reliability of quantification by enhancing both specificity and 
accuracy of analysis (Rifai, Gillette et al. 2006). We applied SID-SRM for targeted 
quantification of eight of the proteins discovered in the screening phase and ten 
literature derived candidate markers in a larger patient cohort (n=125) as described in 
Section 3.3. Due to the limited access of CSF available for fractionation, we chose to 
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focus our studies on high/medium abundant proteins in which endogenous peptides 
were detectable in neat CSF. The selection of literature markers and development of 
the SRM-assay was performed by Ann Cathrine Kroksveen, a researcher in the 
Multiple Sclerosis-group at PROBE. She also performed a separate SID-SRM 
analysis including 132 patients (125 used in the presented study), in addition to a few 
more proteins (Kroksveen 2012). By comparing the results, the significant decreased 
CSF level of Apolipoprotein D and Kallikrein-6 was further confirmed in CIS-MS 
and CIS patients compared with OND. Significant decreased abundance of Alpha-1-
acid glycoprotein 1 was also found between RRMS patients and OND. SID-SRM 
analysis in 132 patients confirmed decreased abundance of Cystatin C in CIS patients 
compared to OND as found in the presented study. To our knowledge, this is the first 
report of a larger SRM verification study of biomarker candidates in MScl. There 
were some variations between the studies, and this could be due to not having 
quantitative data from all the same patients, as Kroksveen had slightly more patients 
in her study. In addition, not all proteins were quantified in all patients, and this also 
varied between the studies. In SRM analysis a protein is quantified based on signature 
peptides. The abundance of a signature peptide is not necessarily representative for 
the target protein as whole, significant abundance differences of a protein could 
appear depending on which peptide(s) that were used for quantification. This is 
probably due to the region of which the surrogate peptide represents could be potent 
for modifications, or representing a truncation or isoform of the protein (Lange, 
Picotti et al. 2008), therefore monitoring multiple peptides will increase the 
confidence of analysis. This could be one reason why not all literature candidates 
could be verified in this study as their initial quantification was based on different 
peptide sequences. A more likely explanation is that a low number of patients were 
used in the initial discovery experiment, and when we included more patients for 
verification, the results were no longer significant. The same explanation could be 
used for the biomarker candidates that we could not verify from our own discovery 
experiment.  
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4.5	  The	  extent	  of	  disease	  and	  biological	  variation	  	  
In the verification phase of the biomarker pipeline the biological variation that was 
reduced in the screening phase by the pooling strategy was reintroduced. This was 
clearly demonstrated in the dimethyl-AIMS experiment, in which pronounced 
heterogeneity between the RRMS patients was observed. Biological variations and 
physiological processes such as the Circadian rhythm (Nilsson, Stahlberg et al. 1992), 
the rostro-caudal gradient, CSF flow-rate (Reiber 1994), and influx of plasma-derived 
proteins across the BBB, in addition to lifestyle, gender and age may influence the 
CSF protein composition. When screening CSF samples for differentially abundant 
proteins between MScl and controls, the pooling strategy reduced the biological 
heterogeneity. When pooling samples, it is important to recognize that if one patient 
included in a pool differs significantly from the rest, this one patient will affect the 
whole pool indicating an artificial abundance difference. As the regulation level for 
Complement C3 and Cystatin C observed in the qualification experiment contradicted 
the data obtained from the discovery, this could point towards the presence of outliers 
in one or more of the pools. 24 of the total 125 patients included in the extended SID-
SRM verification study were also included in the initial screening phase. When 
analyzing these patients separately, although not significant, the same direction of 
regulation was observed as in the discovery experiment. Hence, the introduction of 
more patients in the verification study appeared to change the results for these 
proteins. The concentration of Serum albumin has been reported to vary from 0.097-
0.403 g/L between CSF samples from neurologically normal individuals (Stoop, 
Coulier et al. 2010). Similar variations are typically significant for high abundant 
plasma proteins in CSF, such as Transthyretin and Haptoglobulin (Stoop, Coulier et 
al. 2010). Transthyretin was found to be significantly increased in CSF levels of MScl 
patients both in the screening phase (Section 3.1) as well as in the qualification 
experiment (Section 3.2), but not in the SID-SRM study. This could be explained by 
the reported high inter-individual variation of Transthyretin, which easily could lead 
to significant differences if a few patients are studied, as was the case for the 
discovery and qualification study. For CSF biomarker discovery it is essential to have 
an understanding of natural biological variation between individuals. Hence, CSF 
proteins with known high inter-individual variation should be assessed with caution as 
biomarker candidates in MScl. Taken together, we can conclude that increasing the 
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number of patients and controls in the screening phase will average out the biological 
variation and increase the statistical power of biomarker discovery experiments. 
 
4.6	  Promising	  biomarker	  candidates	  for	  multiple	  sclerosis	  	  
In the presented study we successfully identified proteins that may be involved in the 
pathology of MScl. The most interesting proteins from the presented study were 
Alpha-1-acid glycoprotein 1, Apolipoprotein D, Cystatin C, Kallikrein-6 and 
Secretogranin-1. The pathology of MScl is complex, involving both neuro-
inflammatory and neurodegenerative processes.  
4.6.1	  Markers	  for	  immune	  engagement	  and	  inflammation	  	  
The first event in MScl pathology is expected to be of inflammatory character 
(Bielekova and Martin 2004) in which cellular inflammatory reactions are 
accompanied by disruption of the BBB and the entry of plasma proteins into the CNS 
(Lucchinetti, Bruck et al. 2001). The decreased abundance of Alpha-1-acid 
glycoprotein 1 found in the discovery experiment was confirmed by dimethyl-AIMS 
and SID-SRM analysis. Alpha-1-acid glycoprotein 1 is produced in response to 
inflammation and appears to function in modulating the activity of the immune 
system during acute phase reactions (Fournier, Medjoubi et al. 2000).  
	  
4.6.2	  Markers	  for	  demyelination	  and	  neurodegeneration	  	  	  
Clearance of myelin debris from demyelinating axons may have important functional 
implications in MScl pathology. Apolipoprotein D, Cystatin C and Kallikrein-6 are 
involved in such processes. In the SRM verification study, the differential abundance 
of Apolipoprotein D was significant in several group comparisons (Section 3.3). Its 
abundance was significantly decreased in RRMS compared to OIND and OND, and 
in combining all MScl compared to the two control groups. Apolipoprotein D is 
involved in the removal of lipid during nerve degeneration and has previously been 
reported as a biomarker candidate in MScl (Reindl, Knipping et al. 2001). Decreased 
abundance of Apolipoprotein D have potential as marker for neurodegeneration and 
MScl due to its absence reported to cause decreased clearance of myelin during nerve 
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injury, resulting in delayed axonal regeneration and remyelination (Ganfornina, Do 
Carmo et al. 2010). Cystatin C is synthesized locally in the CNS and acts as a 
protease inhibitor of cathepsins. There is increased evidence of a possible role of this 
protein in the pathogenesis of MScl. After myelin destruction, myelin debris must be 
cleared by activated macrophages before the naked axons can be remyelinated. 
Activated macrophages produce the lysosomal protein cathepsins. Decreased 
abundance of Cystatin C and increased abundance of cathepsin B have been reported 
in CSF of MScl patients during a relapse (Nagai, Murakawa et al. 2000). We found 
Cystatin C to be of significantly decreased CSF levels in CIS compared to OND and 
all MScl compared to OND in the SID-SRM verification study. Kallikrein-6 has 
previously been reported with significantly differential abundance in MScl 
(Hammack, Fung et al. 2004). In the SRM verification Kallikrein-6 had significant 
decreased CSF levels in CIS and CIS-MS patients compared to OND. Furthermore, 
combining all MScl patients in one comparison group gave the same significant 
decrease. Kallikrein-6 is a serine protease known to degrade myelin protein 
(Scarisbrick, Blaber et al. 2002) and is found in elevated CSF levels at sites of 
inflammation in active MScl lesions. Markers for demyelination, remyelination and 
axonal damage may be more disease specific for MScl than inflammatory markers. 
 
The four proteins discussed above have a function that fits well with the expected 
pathogenesis of MScl. It would be interesting to study these proteins further, 
regarding their role in the pathogenesis of MScl, and their diagnostic value by 
performing a larger verification study. No single protein found in our studies could 
clearly distinguish MScl patients from controls. Hence, their value as individual 
diagnostic markers appears to be limited, however they could be of value as part of a 
biomarker panel for MScl, where the different included proteins are reflecting 
different aspects of the disease and the sum have a diagnostic value.  
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4.7	   Protein	   level	   fractionation	   and	   mapping	   of	   the	   normal	   CSF	   proteome	  
enabled	  discovery	  of	   size	  dependent	  differential	   abundant	  protein	   variants	  
in	  multiple	  sclerosis	  	  
The mapping experiment gave us the opportunity to examine the size distribution of 
biomarker candidate proteins in CSF (Section 3.4). The protein distribution across the 
gel of a selection of biomarker candidates was examined with the aim to reveal 
potential protein variants (isoforms, truncation products and proteolytic processed 
products). We observed proteins present in lower mass fractions than expected of 
their theoretical masses. We hypothesized that this could be due to enhanced 
proteolytic processing as CSF is naturally high in active proteases, or it could indicate 
the presence of unknown protein variants of the candidate proteins. The truncation 
theory was supported by a high number of non-tryptic peptides revealed for the 
candidate proteins Cystatin C and Secretogranin-1. 
 
The experiment had immediate utility for investigations in MScl. Based on our 
observations in normal CSF, we applied a label-free relative quantification approach 
aiming to obtain an abundance ratio between RRMS and controls of proteins present 
in high and low mass areas of the gel and to investigate if these ratios differed for the 
same proteins. The most striking observation was of Secreogranin-1, which showed 
an opposite CSF regulation level in RRMS comparing the abundance in the two mass 
fractions. The Multiple Sclerosis-group at PROBE has previously reported 
Secretogranin-1 as a promising early diagnostic biomarker candidate, in which the 
protein showed significant decrease in RRMS compared to OIND. Further, it was 
found to be significantly increased in CIS-MS compared to RRMS (Kroksveen 2012). 
Decreased abundance of two Secretogranin-1 peptides has been found in patients with 
clinical definite MScl (Mattsson, Ruetschi et al. 2007). These findings could indicate 
the abundance of Secretogranin-1 to decrease during the disease course of MScl. Our 
findings indicates that the full-length protein present in the high mass fraction is 
highly increased in MScl, while protein variants of lower mass, potentially being 
truncation products, are decreased in CSF levels in RRMS patients compared to 
control. Its observed regulation in MScl and its biological role in synaptic vessel 
(Taupenot, Harper et al. 2003) makes Secretogranin-1 an interesting biomarker 
candidate which should be further analyzed. Further adding to its significance, 
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Secretogranin-1 is a proprotein known to be proteolytic processed in vivo giving rise 
to biologically active peptide fragments (Benjannet, Leduc et al. 1987). Such peptides 
could reflect biological events and contain diagnostic biomarkers due to the fact that 
in many degenerative diseases there is an abnormal enzymatic degradation of 
proteins, thus rendering the presence of circulating peptides as disease specific and as 
a consequence of diagnostic value. The preliminary results obtained from this pilot 
study show highly interesting indications, however further analysis needs to be 
performed in order to determine the possible significance of Secretogranin-1 derived 
peptide fragments in MScl. 
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Future	  perspectives	  
	  
In respect to the biomarker discovery, a new discovery experiment should be perform 
including more patients to average out the heterogeneity between samples and 
increase the quantification confidence. Extensive fractionation on both protein and 
peptide level could be applied for increased CSF proteome coverage.   
 
SRM analysis should be extended to include more patients and controls to determine 
the clinical utility of the biomarker candidates. Furthermore, more peptides per 
protein should be included for increasing the confidence of quantification. The CSF 
proteome mapping experiment could serve as a reference library of detectable 
peptides and proteins.  
 
It would be of great interest to investigate the regulation level of Secretogranin-1 
peptides in MScl pathogenesis. We identified a total of 72 peptides mapping to 
Secretogranin-1. These peptides could serve as signature peptide for Secretogranin-1 
protein variants for SID-SRM analysis.  
 
In addition, as CSF naturally contains high concentrations of proteases, the 
neurodegenerative aspects regarding abnormal enzymatic degradation of proteins in 
CSF of MScl patients could be addressed by using protease inhibitors to investigate if 
the CSF peptides results from in vivo processing or due to sample treatment prior MS 
analysis.  
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6 Appendix	  
Due to the size and format an Additional appendix (Supplementary Tables 3.1B-3.5B) 
is available at a local computer (EIR server) at PROBE.	  
6.1	   Patient	   information	   for	   patients	   included	   in	   the	   biomarker	   discovery	  
experiment	  	  
Pool	   Diagnosis	   Gender	   Age	  at	  LP	  
Protein	  
conc.	  
(μg/mL)	  
OCB	  MScl	  1	   RRMS	   F	   47	   638	   Positive	  	   RRMS	   M	   31	   502	   Positive	  	   RRMS	   F	   38	   411	   Positive	  	   RRMS	   F	   28	   442	   Positive	  	   RRMS	   F	   51	   404	   Positive	  MScl	  2	   RRMS	   F	   35	   325	   Positive	  	   RRMS	   F	   45	   235	   Positive	  	   RRMS	   F	   33	   396	   Positive	  	   RRMS	   M	   59	   825	   Positive	  	   RRMS	   F	   45	   598	   Positive	  MScl	  3	   CIS	  (MS)	   M	   43	   339	   Positive	  	   PPMS	   F	   41	   511	   Positive	  	   RRMS	   F	   35	   229	   Positive	  	   RRMS	   F	   42	   361	   Positive	  	   RRMS	   F	   39	   266	   Positive	  	   RRMS	   F	   46	   438	   Positive	  OIND	  1	   Meningitis	   F	   31	   1370	   Negative	  	   Bells	  palsy	   F	   35	   834	   Negative	  	   GBS	   M	   53	   1140	   Negative	  	   GBS	   M	   32	   953	   Negative	  	   Meningoradikulitt	   M	   35	   351	   Negative	  OIND	  2	   PML	   F	   89	   755	   Negative	  	   Neuroborreliosis	   F	   56	   426	   Negative	  	   Neuroborreliosis	   M	   19	   433	   Negative	  	   Rombencephalitt	   M	   18	   344	   Positive	  	   Borreliosis	   F	   59	   374	   Negative	  OND	  3	   Pain	   M	   71	   366	   Negative	  	   ALS	   F	   58	   399	   Negative	  	   Asthenia	   M	   27	   425	   Negative	  	   Small-­‐vessel-­‐disease	   M	   62	   526	   Negative	  	   Parkinsonism	   M	   69	   668	   Negative	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6.2	  Patient	  information	  for	  patients	  included	  in	  the	  biomarker	  qualification	  
experiment	  	  
Patient	   Diagnosis	   Gender	   Age	  at	  LP	  
Protein	  
conc.	  
(μg/mL)	  
OCB	  MScl	   RRMS	   F	   28	   411	   Positive	  MScl	   RRMS	   F	   32	   394	   Positive	  MScl	   RRMS	  	   F	   43	   291	   Positive	  MScl	   RRMS	   F	   43	   469	   Positive	  MScl	   RRMS	   F	   28	   490	   Positive	  MScl	   RRMS	   F	   23	   477	   Positive	  MScl	   RRMS	   F	   37	   508	   Positive	  MScl	   RRMS	   F	   64	   378	   Positive	  MScl	   RRMS	   F	   42	   361	   Positive	  MScl	   RRMS	   F	   46	   438	   Positive	  OIND	   Latent	  neurosyfilis	   F	   28	   623	   Negative	  OIND	   Zoster	  nevralgi	   F	   58	   707	   Positive	  OIND	   Nevroboreliosis	   F	   45	   590	   Positive	  OIND	   Bells	  parasis	   M	   26	   713	   Positive	  OIND	   PML	   F	   89	   755	   Positive	  OIND	   PML	   M	   35	   529	   Negative	  OIND	   Parestestier	   F	   47	   376	   Negative	  OIND	   Vasculitt	   F	   27	   482	   Negative	  OIND	   Rombencephalitt	   M	   18	   344	   Positive	  OIND	   Boreliosis	   F	   59	   374	   Negative	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6.3	  Patient	  information	  for	  patients	  included	  in	  the	  biomarker	  verification	  	  
Patient	   Gender	   Age	  at	  LP	  
Protein	  
conc.	  
(μg/mL)	  
OCB	  CIS	   F	   47	   355	   Positive	  CIS	   F	   37	   313	   Positive	  CIS	   F	   36	   423	   Positive	  CIS	   F	   25	   427	   Positive	  CIS	   F	   17	   328	   Positive	  CIS	   F	   25	   436	   Positive	  CIS	   F	   33	   477	   Positive	  CIS	   M	   38	   365	   Positive	  CIS	   M	   22	   372	   Positive	  CIS	   M	   27	   422	   Positive	  CIS	   F	   27	   496	   Positive	  CIS	   F	   53	   481	   Positive	  CIS	   F	   19	   355	   Positive	  CIS-­‐MS	   F	   26	   490	   Positive	  CIS-­‐MS	   F	   34	   512	   Positive	  CIS-­‐MS	   F	   20	   426	   Positive	  CIS-­‐MS	   M	   59	   773	   Positive	  CIS-­‐MS	   M	   43	   551	   Positive	  CIS-­‐MS	  	   F	   37	   338	   Positive	  CIS-­‐MS	   F	   34	   430	   Positive	  CIS-­‐MS	   F	   26	   385	   Positive	  CIS-­‐MS	   M	   33	   412	   Positive	  CIS-­‐MS	   M	   33	   546	   Positive	  CIS-­‐MS	   F	   19	   341	   Positive	  CIS-­‐MS	  	   F	   30	   340	   Positive	  CIS-­‐MS	   F	   52	   358	   Positive	  CIS-­‐MS	   F	   30	   986	   Positive	  RRMS	   M	   45	   522	   Positive	  RRMS	   F	   37	   455	   Positive	  RRMS	   M	   24	   494	   Negative	  RRMS	   M	   38	   482	   Positive	  RRMS	   F	   26	   543	   Positive	  RRMS	   F	   59	   426	   Positive	  RRMS	   F	   36	   336	   Positive	  RRMS	   M	   33	   578	   Positive	  RRMS	   F	   42	   373	   Positive	  RRMS	   F	   26	   525	   Positive	  RRMS	   F	   28	   399	   Positive	  RRMS	   F	   48	   562	   Positive	  RRMS	   F	   30	   544	   Positive	  RRMS	   F	   31	   502	   Positive	  RRMS	   F	   38	   472	   Positive	  RRMS	   F	   28	   442	   Positive	  RRMS	   F	   28	   411	   Positive	  RRMS	   F	   51	   404	   Positive	  RRMS	   F	   35	   338	   Positive	  RRMS	   F	   39	   235	   Positive	  RRMS	   F	   33	   396	   Positive	  RRMS	   F	   32	   394	   Positive	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RRMS	   F	   29	   294	   Positive	  RRMS	   F	   43	   291	   Positive	  RRMS	   F	   43	   469	   Positive	  RRMS	   F	   28	   490	   Positive	  RRMS	   F	   23	   477	   Positive	  RRMS	   F	   37	   508	   Positive	  RRMS	   F	   45	   598	   Positive	  RRMS	   M	   29	   339	   Positive	  RRMS	   F	   35	   229	   Positive	  RRMS	   F	   64	   378	   Positive	  RRMS	   F	   42	   361	   Positive	  RRMS	   F	   39	   266	   Positive	  RRMS	   F	   45	   438	   Positive	  OIND	   F	   41	   897	   Negative	  OIND	   F	   48	   423	   No	  info.	  OIND	   M	   71	   502	   Negative	  OIND	   F	   60	   462	   Negative	  OIND	   F	   39	   426	   Positive	  OIND	   M	   54	   400	   Negative	  OIND	   F	   45	   345	   Positive	  OIND	   F	   40	   621	   Negative	  OIND	   F	   26	   263	   Negative	  OIND	   M	   43	   621	   Positive	  OIND	   M	   42	   922	   Negative	  OIND	   M	   59	   358	   Negative	  OIND	   F	   52	   354	   Negative	  OIND	   F	   62	   619	   Negative	  OIND	   F	   40	   385	   Negative	  OIND	   F	   31	   1370	   Negative	  OIND	   F	   35	   834	   Negative	  OIND	   F	   45	   623	   Negative	  OIND	   F	   58	   707	   Negative	  OIND	   M	   53	   1140	   Negative	  OIND	   M	   26	   713	   Positive	  OIND	   F	   65	   576	   Negative	  OIND	   M	   31	   953	   Negative	  OIND	   M	   35	   351	   Negative	  OIND	   F	   89	   755	   Negative	  OIND	   M	   35	   529	   Positive	  OIND	   F	   47	   376	   Negative	  OIND	   F	   27	   482	   Negative	  OIND	   F	   63	   426	   Negative	  OIND	   M	   43	   433	   Negative	  OIND	   M	   18	   344	   Positive	  OIND	   F	   59	   374	   Negative	  OND	   M	   62	   435	   Negative	  OND	   F	   42	   266	   Negative	  OND	   F	   66	   637	   Negative	  OND	   M	   72	   439	   Negative	  OND	   F	   73	   592	   Negative	  OND	   M	   63	   674	   Negative	  OND	   M	   59	   467	   Negative	  OND	   F	   51	   505	   Negative	  OND	   F	   38	   378	   Negative	  OND	   F	   43	   325	   Negative	  OND	   F	   50	   354	   Negative	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OND	   F	   53	   569	   Negative	  OND	   M	   24	   325	   Negative	  OND	   F	   52	   403	   Negative	  OND	   M	   41	   654	   Negative	  OND	   M	   68	   542	   Negative	  OND	   M	   45	   442	   Negative	  OND	   M	   61	   631	   Negative	  OND	   F	   32	   336	   Negative	  OND	   F	   64	   314	   Negative	  OND	   F	   58	   399	   Negative	  OND	   M	   27	   425	   Negative	  OND	   F	   54	   520	   Negative	  OND	   M	   69	   668	   Negative	  OND	   F	   31	   303	   Negative	  OND	   M	   55	   566	   Negative	  OND	   M	   51	   378	   Negative	  OND	   M	   43	   496	   Negative	  OND	   M	   40	   372	   Negative	  OND	   M	   71	   366	   Negative	  OND	   M	   62	   526	   Negative	  *OIND	  and	  OND	  was	  diagnosed	  with	  similar	  categories	  of	  diseases	  as	  in	  Supplemetary	  Table	  6.1	  and	  6.2.	  	  	  
6.4	   Patient	   information	   of	   non-­‐neurological	   patients	   included	   for	  
characterization	  of	  the	  normal	  human	  CSF	  proteome	  
	  
Patient	   Gender	   Age	  at	  LP	   Protein	  conc.	  (μg/mL)	  NN	   F	   87	   280	  NN	   M	   61	   376	  NN	   M	   36	   562	  NN	   M	   80	   629	  NN	   M	   79	   550	  NN	   F	   82	   555	  NN	   M	   60	   666	  NN	   M	   71	   590	  NN	   F	   64	   314	  NN	   M	   68	   584	  NN	   M	   19	   276	  NN	   M	   58	   599	  NN	   M	   39	   531	  NN	   F	   74	   521	  NN	   M	   25	   353	  NN	   F	   28	   379	  NN	   F	   40	   289	  NN	   M	   63	   511	  NN	   F	   86	   496	  NN	   F	   45	   281	  NN	   M	   19	   407	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6.5	   Patient	   information	   of	   patients	   included	   in	   the	   evaluation	   of	   size	  
dependent	   differential	   abundance	   of	   CSF	   protein	   variants	   in	   multiple	  
sclerosis	  
	  
Patient	   Gender	   Age	  at	  LP	   Protein	  conc.	  (μg/mL)	  RRMS	   F	   43	   469	  RRMS	   F	   28	   490	  RRMS	   F	   22	   476	  RRMS	   F	   36	   508	  RRMS	   F	   45	   438	  OIND	   F	   27	   482	  OIND	   F	   28	   623	  OIND	   M	   26	   713	  OIND	   F	   47	   375	  OIND	   F	   89	   755	  	  	  
6.6	  Batch	  number	  for	  SISs	  ordered	  for	  the	  respective	  target	  proteins	  for	  SID-­‐
SRM	  assays	  	  
Supplier	   Protein	   Batch	  number	  
Thermo	  
Scientific	  
Neuroserpin	   OR16024	  	   Alpha-­‐1-­‐acid	  glycoprotein	  1	   SO303458	  	   Alpha-­‐2-­‐macroglobulin	   OR284584	  	   Ceruloplasmin	   SO303458	  	   Complement	  C3	   SO303458	  	   Transthyretin	   OR284584	  	   Cystatin	  C	   SO303458	  	   Alpha-­‐1-­‐antichymotrypsin	   OR16024	  	   Apolipoprotein	  D	   OR286250	  	   Clusterin	   OR284584	  	   Contactin-­‐1	  	   OR286250	  	   Kallikrein-­‐6	   OR284584	  	   Leucine-­‐rich	  alpha-­‐2-­‐glycoprotein	   OR16024	  	   Secretogranin-­‐1	   SO303458	  	   Secretogranin-­‐2	   SO303458	  	   Serotransferrin	   SO303458	  	   Serum	  albumin	   SO303458	  	   Hemoglobin	  beta-­‐1	   OR284584	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6.7	  Proteins	  and	  peptides	  used	  for	  SRM	  verification	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  
Protein ID. Acc. no Peptide used in SRM Transition used for quantification 
Endogenous peptide SIS peptide 
CE 
Q1 Q3 Q1 Q3 
Alpha-1-acid 
glycoprotein P02763 
TEDTIFLR y6 498 764 503.0 774.0 48 
       
Alpha-1-
antichymotrypsin P01011 
EQLSLLDR y5 487 603 492.0 613.0 38 
       
       
Alpha-2-
macroglobulin P01023 
AIGYLNTGYQR  628.2 738.3 633.2 748.3 37 
 y6      
Neuroserpin Q99574 QEVPLATLEPLVK y10 718.9 1080.6 722.9 1088.6 37 
Apolipoprotein D P05090 NILTSNNIDVK y8 615.9 890.4 619.9 898.4 46 
Ceruloplasmin P00450 GAYPLSIEPIGVR y8 686.8 870.5 691.8 880.5 46 
Clusterin P10909 IDSLLENDR y5 537.6 646.3 542.6 656.3 35 
Complement C3 P01024 ISLPESLK y5 444 573.3 448 581.3 32 
Secretogranin 1  GEAGAPGEEDIQGPTK y11 779 1170 783 1178 39 
Contactin-1 Q12860 
DGEYVVEVR y6 533.4 764.5 538.4 774.5 14 
       
Cystatin C P01034 LVGGPMDASVEEEGVR y9 823.9 975.4 828.9 985.4 26 
Kallikrein-6 Q92876 LSELIQPLPLER y6 704.3 724.4 709.3 734.4 25 
Leucine-rich 
alpha-2-
glycoprotein 
P02750 DLLLPQPDLR y6 590.4 725.4 595.4 735.4 18 
Prostaglandin D2 
synthase P41222 
AQGFTEDTIVFLPQTDK Interference in all transitions N/A N/A N/A N/A N/A 
WFSAGLASNSSQLR Interference in all transitions N/A N/A N/A N/A N/A 
Secretogranin 2 P13521 
IILEALR y5 415 601 420 611 38 
       
Semaphorin-7A O75326 VYLFDFPEGK y8 607.7 952.4 611.7 960.4 20 
Serotransferrin P02787 YLGEEYVK y6 501 724.3 505 732.3 16 
Serum albumin P02768 LVNEVTEFAK y8 575.8 937.5 579.8 945.5 34 
Transthyretin P02766 AADDTWEPFASGK y8 697.7 921.4 701.7 929.4 45 
Haptoglobin P00738 TEGDGVYTLNNEK y7 720.3 881.4 724.3 889.4 29 
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6.8	  Biomarker	  candidates	  with	  literature	  references	  	  
Protein	   Accession	  number	   Reference	  
Alpha-­‐1-­‐acid	  
glycoprotein	  
P02763	   (Rithidech,	  Honikel	  et	  al.	  2009)	  
Alpha-­‐2-­‐
macroglobulin	  
P01023	   (Stoop,	  Dekker	  et	  al.	  2008)	  (Ottervald,	  Franzen	  et	  al.	  2010)	  
Ceruloplasmin	   P00450	   (Stoop,	  Dekker	  et	  al.	  2008)	  (Ottervald,	  Franzen	  et	  al.	  2010)	  (Comabella,	  Fernandez	  et	  al.	  2010)	  
Complement	  C3	   P01024	   (Stoop,	  Dekker	  et	  al.	  2008)	  (Ottervald,	  Franzen	  et	  al.	  2010)	  
Neurosepin	   	   	  
Prostaglandin-­‐H2	  D-­‐
isomerase	  
P41222	   (Stoop,	  Dekker	  et	  al.	  2008)	  
Semaphorin-­‐7A	   O75326	   (Comabella,	  Fernandez	  et	  al.	  2010)	  (Comabella,	  Fernandez	  et	  al.	  2010)	  
Transthyretin	   P02766	   (Stoop,	  Dekker	  et	  al.	  2008)	  (Ottervald,	  Franzen	  et	  al.	  2010)	  
Osteopontin	   P10451	   	  
Amyloid	  beta	  A4	  
protein	  
P05067	   (Ottervald,	  Franzen	  et	  al.	  2010)	  
Pigment	  epithelium	  
derived	  factor	  
P36955	   (Ottervald,	  Franzen	  et	  al.	  2010)	  
Zinc-­‐alpha-­‐2-­‐
glycoprotein	  
P25311	   	  
Cystatin-­‐C	   P01034	   	  
Alpha-­‐1-­‐anti	  trypsin	   P01009	   (Ottervald,	  Franzen	  et	  al.	  2010)	  
Haptoglobin	   	   (Comabella,	  Fernandez	  et	  al.	  2010)	  
Ectonucleotide	  
pyrophosphatase	  
Q13822	   	  
Hemopexin	   P02790	   (Ottervald,	  Franzen	  et	  al.	  2010)	  	  	  	  
